US20010003799A1 - Apparatus and method for adjunct (add-on) therapy for depression, migraine, neuropsychiatric disorders, partial complex epilepsy, generalized epilepsy and involuntary movement disorders utilizing an external stimulator - Google Patents
Apparatus and method for adjunct (add-on) therapy for depression, migraine, neuropsychiatric disorders, partial complex epilepsy, generalized epilepsy and involuntary movement disorders utilizing an external stimulator Download PDFInfo
- Publication number
- US20010003799A1 US20010003799A1 US09/727,570 US72757000A US2001003799A1 US 20010003799 A1 US20010003799 A1 US 20010003799A1 US 72757000 A US72757000 A US 72757000A US 2001003799 A1 US2001003799 A1 US 2001003799A1
- Authority
- US
- United States
- Prior art keywords
- electrode
- lead
- receiver
- electrical signals
- nerve
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 28
- 238000002560 therapeutic procedure Methods 0.000 title claims abstract description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 17
- 208000035475 disorder Diseases 0.000 title claims abstract description 17
- 208000019695 Migraine disease Diseases 0.000 title claims abstract description 10
- 206010027599 migraine Diseases 0.000 title claims abstract description 7
- 206010015037 epilepsy Diseases 0.000 title abstract description 13
- 208000003078 Generalized Epilepsy Diseases 0.000 title abstract description 9
- 201000001993 idiopathic generalized epilepsy Diseases 0.000 title abstract description 7
- 208000012661 Dyskinesia Diseases 0.000 title abstract description 4
- 230000017311 musculoskeletal movement, spinal reflex action Effects 0.000 title abstract description 4
- 230000000638 stimulation Effects 0.000 claims abstract description 49
- 210000001186 vagus nerve Anatomy 0.000 claims abstract description 38
- 210000003792 cranial nerve Anatomy 0.000 claims abstract description 16
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 46
- 239000000835 fiber Substances 0.000 claims description 41
- 150000003431 steroids Chemical class 0.000 claims description 26
- 229920001296 polysiloxane Polymers 0.000 claims description 25
- 238000000576 coating method Methods 0.000 claims description 21
- 239000011248 coating agent Substances 0.000 claims description 19
- 230000004936 stimulating effect Effects 0.000 claims description 15
- 239000000017 hydrogel Substances 0.000 claims description 10
- 239000004814 polyurethane Substances 0.000 claims description 10
- 230000008878 coupling Effects 0.000 claims description 9
- 238000010168 coupling process Methods 0.000 claims description 9
- 238000005859 coupling reaction Methods 0.000 claims description 9
- 238000009413 insulation Methods 0.000 claims description 9
- 229920002635 polyurethane Polymers 0.000 claims description 9
- 238000011282 treatment Methods 0.000 claims description 9
- 239000004020 conductor Substances 0.000 claims description 7
- 230000007246 mechanism Effects 0.000 claims description 6
- 230000000845 anti-microbial effect Effects 0.000 claims description 5
- 210000000196 olfactory nerve Anatomy 0.000 claims description 5
- 229920001343 polytetrafluoroethylene Polymers 0.000 claims description 5
- 239000004810 polytetrafluoroethylene Substances 0.000 claims description 5
- 229910001260 Pt alloy Inorganic materials 0.000 claims description 4
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 4
- 229910000575 Ir alloy Inorganic materials 0.000 claims description 3
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- -1 polytetrafluoroethylene Polymers 0.000 claims description 2
- 230000003213 activating effect Effects 0.000 claims 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- NRTOMJZYCJJWKI-UHFFFAOYSA-N Titanium nitride Chemical compound [Ti]#N NRTOMJZYCJJWKI-UHFFFAOYSA-N 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 208000020401 Depressive disease Diseases 0.000 abstract description 3
- 238000010586 diagram Methods 0.000 description 39
- 210000005036 nerve Anatomy 0.000 description 33
- 230000000694 effects Effects 0.000 description 26
- 206010010904 Convulsion Diseases 0.000 description 24
- 210000004556 brain Anatomy 0.000 description 20
- 230000005641 tunneling Effects 0.000 description 19
- 229910052697 platinum Inorganic materials 0.000 description 18
- 210000001519 tissue Anatomy 0.000 description 17
- 230000007383 nerve stimulation Effects 0.000 description 15
- 230000000747 cardiac effect Effects 0.000 description 14
- 239000000463 material Substances 0.000 description 13
- 238000005516 engineering process Methods 0.000 description 10
- 230000001515 vagal effect Effects 0.000 description 10
- 210000003169 central nervous system Anatomy 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 229910052741 iridium Inorganic materials 0.000 description 8
- GKOZUEZYRPOHIO-UHFFFAOYSA-N iridium atom Chemical compound [Ir] GKOZUEZYRPOHIO-UHFFFAOYSA-N 0.000 description 8
- 210000000627 locus coeruleus Anatomy 0.000 description 8
- 239000003990 capacitor Substances 0.000 description 7
- 230000003176 fibrotic effect Effects 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 230000001953 sensory effect Effects 0.000 description 7
- 210000001679 solitary nucleus Anatomy 0.000 description 7
- 230000008901 benefit Effects 0.000 description 6
- 238000013461 design Methods 0.000 description 6
- 229960003957 dexamethasone Drugs 0.000 description 6
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 6
- 210000002216 heart Anatomy 0.000 description 6
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 210000004727 amygdala Anatomy 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 5
- 210000004126 nerve fiber Anatomy 0.000 description 5
- 210000000278 spinal cord Anatomy 0.000 description 5
- 210000001170 unmyelinated nerve fiber Anatomy 0.000 description 5
- 229910000859 α-Fe Inorganic materials 0.000 description 5
- 229920004934 Dacron® Polymers 0.000 description 4
- 238000011366 aggressive therapy Methods 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- 210000003016 hypothalamus Anatomy 0.000 description 4
- 239000007943 implant Substances 0.000 description 4
- 230000004007 neuromodulation Effects 0.000 description 4
- 239000005020 polyethylene terephthalate Substances 0.000 description 4
- 230000007384 vagal nerve stimulation Effects 0.000 description 4
- 210000004760 visceral afferent Anatomy 0.000 description 4
- 241000282412 Homo Species 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 210000003626 afferent pathway Anatomy 0.000 description 3
- 230000001773 anti-convulsant effect Effects 0.000 description 3
- 230000002567 autonomic effect Effects 0.000 description 3
- 230000036471 bradycardia Effects 0.000 description 3
- 208000006218 bradycardia Diseases 0.000 description 3
- 210000000133 brain stem Anatomy 0.000 description 3
- 210000005056 cell body Anatomy 0.000 description 3
- 230000001054 cortical effect Effects 0.000 description 3
- 210000002049 efferent pathway Anatomy 0.000 description 3
- 238000002513 implantation Methods 0.000 description 3
- 230000030214 innervation Effects 0.000 description 3
- 230000002197 limbic effect Effects 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000036651 mood Effects 0.000 description 3
- 210000004129 prosencephalon Anatomy 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 210000004189 reticular formation Anatomy 0.000 description 3
- 229940076279 serotonin Drugs 0.000 description 3
- 230000000392 somatic effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 210000001103 thalamus Anatomy 0.000 description 3
- KRQUFUKTQHISJB-YYADALCUSA-N 2-[(E)-N-[2-(4-chlorophenoxy)propoxy]-C-propylcarbonimidoyl]-3-hydroxy-5-(thian-3-yl)cyclohex-2-en-1-one Chemical compound CCC\C(=N/OCC(C)OC1=CC=C(Cl)C=C1)C1=C(O)CC(CC1=O)C1CCCSC1 KRQUFUKTQHISJB-YYADALCUSA-N 0.000 description 2
- 208000033001 Complex partial seizures Diseases 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 206010061334 Partial seizures Diseases 0.000 description 2
- 239000004642 Polyimide Substances 0.000 description 2
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 229910045601 alloy Inorganic materials 0.000 description 2
- 239000000956 alloy Substances 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 238000004873 anchoring Methods 0.000 description 2
- 230000003556 anti-epileptic effect Effects 0.000 description 2
- 230000000573 anti-seizure effect Effects 0.000 description 2
- 230000037007 arousal Effects 0.000 description 2
- 230000001174 ascending effect Effects 0.000 description 2
- 210000001715 carotid artery Anatomy 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 210000001638 cerebellum Anatomy 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 238000002635 electroconvulsive therapy Methods 0.000 description 2
- 238000000537 electroencephalography Methods 0.000 description 2
- 230000001037 epileptic effect Effects 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 210000001932 glossopharyngeal nerve Anatomy 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000002109 interictal effect Effects 0.000 description 2
- 210000004731 jugular vein Anatomy 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000003007 myelin sheath Anatomy 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 210000000584 nodose ganglion Anatomy 0.000 description 2
- 230000002474 noradrenergic effect Effects 0.000 description 2
- 230000002450 orbitofrontal effect Effects 0.000 description 2
- 206010033675 panniculitis Diseases 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229920003055 poly(ester-imide) Polymers 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 229920001721 polyimide Polymers 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000010079 rubber tapping Methods 0.000 description 2
- 230000003238 somatosensory effect Effects 0.000 description 2
- QMGVPVSNSZLJIA-FVWCLLPLSA-N strychnine Chemical compound O([C@H]1CC(N([C@H]2[C@H]1[C@H]1C3)C=4C5=CC=CC=4)=O)CC=C1CN1[C@@H]3[C@]25CC1 QMGVPVSNSZLJIA-FVWCLLPLSA-N 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 210000004304 subcutaneous tissue Anatomy 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 239000010936 titanium Substances 0.000 description 2
- 229910052719 titanium Inorganic materials 0.000 description 2
- 230000000472 traumatic effect Effects 0.000 description 2
- 210000003901 trigeminal nerve Anatomy 0.000 description 2
- RFFLAFLAYFXFSW-UHFFFAOYSA-N 1,2-dichlorobenzene Chemical compound ClC1=CC=CC=C1Cl RFFLAFLAYFXFSW-UHFFFAOYSA-N 0.000 description 1
- DUUGKQCEGZLZNO-UHFFFAOYSA-M 5-Hydroxyindoleacetate Chemical compound OC1=CC=C2NC=C(CC([O-])=O)C2=C1 DUUGKQCEGZLZNO-UHFFFAOYSA-M 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010011906 Death Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 229920000557 Nafion® Polymers 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- QMGVPVSNSZLJIA-UHFFFAOYSA-N Nux Vomica Natural products C1C2C3C4N(C=5C6=CC=CC=5)C(=O)CC3OCC=C2CN2C1C46CC2 QMGVPVSNSZLJIA-UHFFFAOYSA-N 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- 206010062519 Poor quality sleep Diseases 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 241001279009 Strychnos toxifera Species 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 210000003208 abducens nerve Anatomy 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 210000002187 accessory nerve Anatomy 0.000 description 1
- 230000036982 action potential Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 208000030963 borderline personality disease Diseases 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 210000003109 clavicle Anatomy 0.000 description 1
- 210000000860 cochlear nerve Anatomy 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 229960002344 dexamethasone sodium phosphate Drugs 0.000 description 1
- PLCQGRYPOISRTQ-FCJDYXGNSA-L dexamethasone sodium phosphate Chemical compound [Na+].[Na+].C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COP([O-])([O-])=O)(O)[C@@]1(C)C[C@@H]2O PLCQGRYPOISRTQ-FCJDYXGNSA-L 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 230000008909 emotion recognition Effects 0.000 description 1
- 230000006353 environmental stress Effects 0.000 description 1
- 230000008579 epileptogenesis Effects 0.000 description 1
- 230000002397 epileptogenic effect Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 210000000256 facial nerve Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 210000000609 ganglia Anatomy 0.000 description 1
- 210000005095 gastrointestinal system Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000008303 genetic mechanism Effects 0.000 description 1
- 210000004326 gyrus cinguli Anatomy 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- QRMZSPFSDQBLIX-UHFFFAOYSA-N homovanillic acid Chemical compound COC1=CC(CC(O)=O)=CC=C1O QRMZSPFSDQBLIX-UHFFFAOYSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229920002529 medical grade silicone Polymers 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 210000001767 medulla oblongata Anatomy 0.000 description 1
- 210000001259 mesencephalon Anatomy 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 210000000478 neocortex Anatomy 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000008587 neuronal excitability Effects 0.000 description 1
- 150000004767 nitrides Chemical class 0.000 description 1
- 210000002589 oculomotor nerve Anatomy 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 230000001734 parasympathetic effect Effects 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 238000011422 pharmacological therapy Methods 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 210000000976 primary motor cortex Anatomy 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000000862 serotonergic effect Effects 0.000 description 1
- 210000004911 serous fluid Anatomy 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 210000002538 spinal trigeminal nucleus Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 229960005453 strychnine Drugs 0.000 description 1
- 230000002739 subcortical effect Effects 0.000 description 1
- 210000003523 substantia nigra Anatomy 0.000 description 1
- 210000004281 subthalamic nucleus Anatomy 0.000 description 1
- 238000006277 sulfonation reaction Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 201000008914 temporal lobe epilepsy Diseases 0.000 description 1
- 230000000542 thalamic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000003076 trochlear nerve Anatomy 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/05—Electrodes for implantation or insertion into the body, e.g. heart electrode
- A61N1/0526—Head electrodes
- A61N1/0529—Electrodes for brain stimulation
- A61N1/0536—Preventing neurodegenerative response or inflammatory reaction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/36014—External stimulators, e.g. with patch electrodes
- A61N1/36017—External stimulators, e.g. with patch electrodes with leads or electrodes penetrating the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/36014—External stimulators, e.g. with patch electrodes
- A61N1/36025—External stimulators, e.g. with patch electrodes for treating a mental or cerebral condition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/3605—Implantable neurostimulators for stimulating central or peripheral nerve system
- A61N1/3606—Implantable neurostimulators for stimulating central or peripheral nerve system adapted for a particular treatment
- A61N1/36064—Epilepsy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/3605—Implantable neurostimulators for stimulating central or peripheral nerve system
- A61N1/3606—Implantable neurostimulators for stimulating central or peripheral nerve system adapted for a particular treatment
- A61N1/36071—Pain
- A61N1/36075—Headache or migraine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/3605—Implantable neurostimulators for stimulating central or peripheral nerve system
- A61N1/3606—Implantable neurostimulators for stimulating central or peripheral nerve system adapted for a particular treatment
- A61N1/36082—Cognitive or psychiatric applications, e.g. dementia or Alzheimer's disease
Abstract
An apparatus and method for adjunct (add-on) therapy of depression, migraine, neuropsychiatric disorders, partial complex epilepsy, generalized epilepsy and involuntary movement disorders comprises an implantable lead-receiver, and an external stimulator having controlling circuitry, a power source, and a coil to inductively couple the stimulator to the lead-receiver. The external stimulator emits electrical pulses to stimulate a cranial nerve such as the left vagus nerve according to a predetermined program. In a second mode of operation, an operator may manually override the predetermined sequence of stimulation.
Description
- This is a Continuation-in-Part application claiming priority from pending prior application Ser. No. 09/178,060 filed Oct. 26, 1998, the prior application being incorporated herein by reference.
- This invention relates generally to electrical stimulation therapy for neurologic and neuropsychiatric disorders, more specifically to neuromodulation therapy for depression, migraine, and neuropsychiatric disorders, as well as adjunct treatment for partial complex, generalized epilepsy and involuntary movement disorders utilizing an implanted lead-receiver and an external stimulator.
- It has been observed clinically that electrical stimulation therapy for seizures produced mood improvement independent of the anti-seizure effects. This discovery led to medical research into the therapeutic effects of electrical stimulation for depression. Medical research has shown beneficial medical effects of vagus nerve stimulation (VNS) for severely depressed patients.
- Vagus nerve stimulation, and the profound effects of electrical stimulation of the vagus nerve on central nervous system (CNS) activity, extends back to the 1930's. Medical studies in clinical neurobiology have advanced our understanding of anatomic and physiologic basis of the anti-depressive effects of vagus nerve stimulation.
- Some of the somatic interventions for the treatment of depression include electroconvulsive therapy (ECT), transcranical magnetic stimulation, vagus nerve stimulation, and deep brain stimulation. The vagus nerve is the 10th cranial nerve, and is a direct extension of the brain. FIG. 1A, shows a diagram of the brain and
spinal cord 24, with its relationship to thevagus nerve 54 and the nucleus tractus solitarius 14. FIG. 1B shows the relationship of thevagus nerve 54 with the other cranial nerves. - Vagus nerve stimulation is a means of directly affecting central function and is less invasive than deep brain stimulation (DBS). As shown in FIG. 1C, cranial nerves have both afferent pathway19 (inward conducting nerve fibers which convey impulses toward the brain) and efferent pathway 21 (outward conducting nerve fibers which convey impulses to an effector). The vagus nerve is composed of 80% afferent sensory fibers carrying information to the brain from the head, neck, thorax, and abdomen. The sensory afferent cell bodies of the vagus reside in the nodose ganglion and relay information to the nucleus tractus solitarius (NTS) 14.
- As shown schematically in FIGS. 1A and 1D, the nucleus of the solitary tract relays this incoming sensory information to the rest of the brain through three main pathways; (1) an autonomic feedback loop, (2) direct projection to the reticular formation in the medulla, and (3) ascending projections to the forebrain largely through the parabrachial nucleus (PBN)20 and the locus ceruleus (LC) 22. The
PBN 20 sits adjacent to the neucleus LC 22 (FIG. 1A). The PBN/LC 20/22 sends direct connections to every level of the forebrain, including the hypothalamus 26, and several thalamic 25 regions that control the insula and orbitofrontal 28 and prefontal cortices. Perhaps important for mood regulation, the PBN/LC 20/22 has direct connections to theamygdala 29 and the bed nucleus of the stria terminalis—structures that are implicated in emotion recognition and mood regulation. - In sum, incoming sensory (afferent) connections ofthe
vagus nerve 54 provide direct projections to many of the brain regions implicated in nueropsychiatric disorders. These connections reveal how vagus nerve stimulation is a portal to the brainstem and connected regions. These circuits likely account for the neuropsychiatric effects of vagus nerve stimulation. - Increased activity of the vagus nerve is also associated with the release of more serotonin in the brain. Much of the pharmacologic therapy for treatment of migraines is aimed at increasing the levels of serotonin in the brain. Therefore, non-pharmacologic therapy of electrically stimulating the vagus nerve would have benefits for adjunct treatment of migraines and other ailments, such as obsessive compulsive disorders, that would benefit from increasing the level of serotonin in the brain.
- The vagus nerve provides an easily accessible, peripheral route to modulate central nervous system (CNS) function. Other cranial nerves can be used for the same purpose, but the vagus nerve is preferred because of its easy accessibility. In the human body there are two vagal nerves (VN), the right VN and the left VN. Each vagus nerve is encased in the carotid sheath along with the carotid artery and jugular vein. The innervation of the right and left vagal nerves is different. The innervation of the right vagus nerve is such that stimulating it results in profound bradycardia (slowing of the heart rate). The left vagal nerve has some innervation to the heart, but mostly innervates the visceral organs such as the gastrointestinal tract. It is known that stimulation of the left vagal nerve does not cause any significant deleterious side effects.
- Complex partial seizure is a common form of epilepsy, and some 30-40% of patients afflicted with this disorder are not well controlled by medications. Some patients have epileptogenic foci that may be identified and resected; however, many patients remain who have medically resistant seizures not amenable to resective surgery. Stimulation of the vagus nerve has been shown to reduce or abort seizures in experimental models. Early clinical trials have suggested that vagus nerve stimulation has beneficial effects for complex partial seizures and generalized epilepsy in humans. In addition, intermittent vagal stimulation has been relatively safe and well tolerated during the follow-up period available in these groups of patients. The minimal side effects of tingling sensations and brief voice abnormalities have not been distressing.
- Most nerves in the human body are composed of thousands of fibers, of different sizes designated by groups A, B and C, which carry signals to and from the brain. The vagus nerve, for example, may have approximately 100,000 fibers ofthe three different types, each carrying signals. Each axon (fiber) of that nerve conducts only in one direction, in normal circumstances. The A and B fibers are myelinated (i.e., have a myelin sheath, constituting a substance largely composed of fat), whereas the C fibers are unmyelinated.
- A commonly used nomenclature for peripheral nerve fibers, using Roman and Greek letters, is given in the table below,
External Diameter Conduction Velocity Group (μm) (m/sec) Myelinated Fibers Aα or IA 12-20 70-120 Aβ: IB 10-15 60-80 II 5-15 30-80 Aγ 3-8 15-40 Aδ or III 3-8 10-30 B 1-3 5-15 Unmyelinted fibers C or IV 0.2-1.5 0.5-2.5 - The diameters of group A and group B fibers include the thicknesses of the myelin sheaths. Group A is further subdivided into alpha, beta, gamma, and delta fibers in decreasing order of size. There is some overlapping of the diameters of the A, B, and C groups because physiological properties, especially the form ofthe action potential, are taken into consideration when defining the groups. The smallest fibers (group C) are unmyelinated and have the slowest conduction rate, whereas the myelinted fibers of group B and group A exhibit rates of conduction that progressively increase with diameter. Group B fibers are not present in the nerves of the limbs; they occur in white rami and some cranial nerves.
- Compared to unmyelinated fibers, myelinated fibers are typically larger, conduct faster, have very low stimulation thresholds, and exhibit a particular strength-duration curve or respond to a specific pulse width versus amplitude for stimulation. The A and B fibers can be stimulated with relatively narrow pulse widths, from 50 to 200 microseconds (μs), for example. The A fiber conducts slightly faster than the B fiber and has a slightly lower threshold. The C fibers are very small, conduct electrical signals very slowly, and have high stimulation thresholds typically requiring a wider pulse width (300-1,000 μs) and a higher amplitude for activation. Selective stimulation of only A and B fibers is readily accomplished. The requirement of a larger and wider pulse to stimulate the C fibers, however, makes selective stimulation of only C fibers, to the exclusion of the A and B fibers, virtually unachievable inasmuch as the large signal will tend to activate the A and B fibers to some extent as well.
- The vagus nerve is composed of somatic and visceral afferents (i.e., inward conducting nerve fibers which convey impulses toward the brain) and efferents (i.e., outward conducting nerve fibers which convey impulses to an effector). Usually, nerve stimulation activates signals in both directions (bi-directionally). It is possible, however, through the use of special electrodes and waveforms, to selectively stimulate a nerve in one direction only (unidirectionally). The vast majority of vagal nerve fibers are C fibers, and a majority are visceral afferents having cell bodies lying in masses or ganglia in the skull. The central projections terminate largely in the nucleus of the solitary tract which sends fibers to various regions of the brain (e.g., the hypothalamus, thalamus, and amygdala).
- The basic premise of vagal nerve stimulation for control of seizures is that vagal visceral afferents have a diffuse central nervous system (CNS) projection, and activation of these pathways has a widespread effect on neuronal excitability.
- The cervical component of the vagus nerve (10th cranial nerve) transmits primarily sensory information that is important in the regulation of autonomic activity by the parasympathetic system. General visceral afferents constitute approximately 80% of the fibers of the nerve, and thus it is not surprising that vagal nerve stimulation (VNS) can profoundly affect CNS activity. With cell bodies in the nodose ganglion, these afferents originate from receptors in the heart, aorta, lungs, and gastrointestinal system and project primarily to the nucleus of the solitary tract which extends throughout the length of the medulla oblongata. A small number of fibers pass directly to the spinal trigeminal nucleus and the reticular formation.
- As might be predicted from the electrophysiologic studies, the nucleus ofthe solitary tract has widespread projection to cerebral cortex, basal forebrain, thalamus, hypothalamus, amygdala, hippocampus, dorsal raphe, and cerebellum as shown in FIG. 1D (fromEpilepsia, vol. 3, suppl.2:1990, page S2).
- Even though observations on the profound effect of electrical stimulation of the vagus nerve on central nervous system (CNS) activity, extends back to the 1930's, in the mid-1980s it was suggested that electrical stimulation of the vagus nerve might be effective in preventing seizures. Early studies on the effects of vagal nerve stimulation (VNS) on brain function focused on acute changes in the cortical electroencephalogram (EEG) of anesthetized animals. Investigators found that VNS could temporarily synchronize or desynchronize the electroencephalogram, depending on the level of anesthesia and the frequency or intensity of the vagal stimulus. These observations had suggested that VNS exerted its anticonvulsant effect by desynchronizing cortical electrical activity. However, subsequent clinical investigations have not shown VNS-induced changes in the background EEGs of humans. A study, which used awake and freely moving animals, also showed no VNS-induced changes in background EEG activity. Taken together, the findings from animal study and recent human studies indicate that acute desynchronization of EEG activity is not a prominent feature of VNS when it is administered during physiologic wakefulness and sleep, and does not explain the anticonvulsant effect of VNS.
- The mechanism by which vagal nerve stimulation (VNS) exerts its influence on seizures is not entirely understood. An early hypotheses had suggested that VNS utilizes the relatively specific projection from the nucleus of the solitary track to limbic structures to inhibit partial seizures, particularly those involving cortex, which regulates autonomic activity or visceral sensations such as in temporal lobe epilepsy. Afferent VNS at the onset of a partial seizure could abort the seizure in the same way somatosensory stimuli can abort a seizure from the rolandic cortex; however, chronic intermittent stimulation may also produce an alteration in limbic circuitry that outlasts the stimulus and decreases epileptogenesis or limits seizure spread. Support for this hypothesis comes from studies of fos immunoreactivity in the brain of rats in response to VNS. Fos is a nuclear protein resulting from expression of early immediate genes in highly active neurons. VNS causes a specific fos immunolabeling in amygdala and limbic neocortex, suggesting that the antiepileptic effect may be mediated in these areas. Such activation of genetic mechanisms could account for the apparent sustained antiepileptic effect of intermittent stimulation.
- Another possible mechanism that is being explored to explain an antiseizure effect of VNS is activation of the brainstem noradrenergic nuclei, lucus ceruleus and A5, which also show fos immunolabeling. Noradrenergic mechanisms are well known to influence seizure activity in genetic epilepsy-prone rats, and the anticonvulsant effects of VNS against maximal electroshock seizures can be blocked inactivation of the loc. ceruleus. Woodbury and Woodbury (1990) suggested that VS acts through increasing release of glycine or GABA since seizures induced by both PTZ and strychnine can be blocked by VNS. Other neruotransmitter systems may also be implicated since VNS increases cerebrospinal fluid homovanilic acid and 5-hydroxyindoleacetate, suggesting modulation of dopaminergic and serotonergic systems. Finally, a nonspecific alteration of activity in the brainstem reticular system with subsequent arousal must be considered.
- VNS appears to have similar efficacy in both partial and generalized seizures in experimental models and in human epilepsy consistent with a nonspecific effect. Furthermore, the same inhibition of interictal corticalspike activity as seen with VNS occurs in animals during electrical stimulation of the midbrain reticular formation or with thermal stimulation of somatosensory nerves in the rat tail. Reduction of experimental generalized spike wave by arousal has also been documented. Similarly, nonspecific afferent stimulation has been well demonstrated in humans to suppress focal spikes, generalized spike waves, and seizures.
- VNS may inhibit seizures directly at the level of cerebral cortical neuronal irritability, or at the level of diffuse ascending subcortical projection systems, or both. Thus, VNS is also well suited for the treatment of medication-resistant symptomatic generalized epilepsy (SGE), in which, characteristically both focal and generalized features are found on interictal EEGs and also in clinical seizure types.
- One type of prior non-pharmacological therapy for depression, migraines, neuropsychiatric disorders, and epilepsy is generally directed to the use of an implantable lead and an implantable pulse generator technology or “cardiac pacemaker-like” technology. In these applications, the pulse generator is programmed via a personnel computer (PC) based programmer that is modified and adapted with a programmer wand which is placed on top of the skin over the pulse generator implant site. Each parameter is programmed independent of the other parameters. Therefore, millions of different combinations of programs are possible. In the instant patent, preferably approximately nine programs are pre-selected.
- U.S. Pat. No. 3,796,221 (Hagfors) is directed to controlling the amplitude, duration and frequency of electrical stimulation applied from an externally located transmitter to an implanted receiver by inductively coupling. Electrical circuitry is schematically illustrated for compensating for the variability in the amplitude of the electrical signal available to the receiver because of the shifting of the relative positions of the transmitter-receiver pair. By highlighting the difficulty of delivering consistent pulses, this patent points away from applications such as the current application, where consistent therapy needs to be continuously sustained over a prolonged period of time (24 hours a day for years). The methodology disclosed is focused on circuitry within the receiver, which would not be sufficient when the transmitting coil and receiving coil assume significantly different orientation, which is likely in the current application. The present invention discloses a novel approach for this problem.
- U.S. Pat. No. 5,304,206 (Baker, Jr. et al) is directed to activation techniques for implanted medical stimulators. The system uses either a magnet to activate the reed switch in the device, or tapping which acts through the piezoelectric sensor mounted on the case of the implanted device, or a combination of magnet and tapping sequence.
- U.S. Pat. Nos. 4,702,254, 4,867,164 and 5,025,807 (Zabara) generally disclose animal research and experimentation related to epilepsy and the like and are directed to stimulating the vagus nerve by using pacemaker technology, such as an implantable pulse generator. These patents are based on several key hypotheses, some of which have since been shown to be incorrect. The pacemaker technology concept consists of a stimulating lead connected to a pulse generator (containing the circuitry and DC power source) implanted subcutaneously or submuscularly, somewhere in the pectoral or axillary region, with an external personal computer (PC) based programmer. Once the pulse generator is programmed for the patient, the fully functional circuitry and power source are fully implanted within the patient's body. In such a system, when the battery is depleted, a surgical procedure is required to disconnect and replace the entire pulse generator (circuitry and power source). These patents neither anticipate practical problems of an inductively coupled system for adjunct therapy of epilepsy, nor suggest solutions to the same for an inductively coupled system for adjunct therapy of partial complex or generalized epilepsy. FIG. 4 in all three above Zabara patents show the stimulation electrode around the right vagus nerve. It is well known that stimulation of right vagus can lead to profound bradycardia (slowing of the heart rate), an unwanted complication.
- U.S. Pat. No. 5,299,569 (Wernicke et al.) is directed to the use of implantable pulse generator technology for treating and controlling neuropsychiatric disorders including schizophrenia, depression, and borderline personality disorder.
- U.S. Pat. No. 5,752,979 (Benabid) is directed to a method of controlling epilepsy with stimulation directly into the brain, utilizing an implantable generator. More specifically, Benabid discloses electrically stimulating the external segment of the globus palliaus nucleus of the brain causing increased excitation, thereby increasing inhibition of neural activity in the subthalamic nucleus and reducing excitatory input to the substantia nigra leading to a reduction in the occurrence of seizures.
- U.S. Pat. No. 5,540,734 (Zabara) is directed to stimulation of one or both of a patient's trigeminal and glossopharyngeal nerve utilizing an implanted pulse generator.
- U.S. Pat. No. 5,031,618 (Mullett) discloses a position sensor for chronically implanted neuro stimulator for stimulating the spinal cord. The position sensor, located in a chronically implanted programmable spinal cord stimulator, modulates the stimulation signals depending on whether the patient is erect or supine.
- U.S. Pat. No. 4,573,481 (Bullara) is directed to an implantable helical electrode assembly configured to fit around a nerve. The individual flexible ribbon electrodes are each partially embedded in a portion of the peripheral surface of a helically formed dielectric support matrix.
- U.S. Pat. No. 3,760,812 (Timm et al.) discloses nerve stimulation electrodes that include a pair of parallel spaced apart helically wound conductors maintained in this configuration.
- U.S. Pat. No. 4,979,511 (Terry) discloses a flexible, helical electrode structure with an improved connector for attaching the lead wires to the nerve bundle to minimize damage.
- An implantable pulse generator and lead with a PC based external programmer is advantageous for cardiac pacing applications for several reasons, including:
- 1) A cardiac pacemaker must sense the intrinsic activity of the heart, because cardiac pacemakers deliver electrical output primarily during the brief periods when patients either have pauses in their intrinsic cardiac activity or during those periods of time when the heart rate drops (bradycardia) below a certain pre-programmed level. Therefore, for most of the time, in majority of patients, the cardiac pacemaker “sits” quietly monitoring the patient's intrinsic cardiac activity.
- 2) The stimulation frequency for cardiac pacing is typically close to 1 Hz, as opposed to approximately 20 Hz or higher, typically used in nerve stimulation applications.
- 3) Patients who require cardiac pacemaker support are typically in their 60's, 70's or 80's years of age.
- The combined effect of these three factors is that the battery in a pacemaker can have a life of 10-15 years. Most patients in whom a pacemaker is indicated are implanted only once, with perhaps one surgical pulse generator replacement.
- In contrast, patients with partial complex epilepsy or generalized epilepsy in whom electrical stimulation is beneficial are much younger as a group, typically ranging from 12 to 45 years in age. Also, stimulation frequency is typically 20 Hz or higher, and the total stimulation time per day is much longer than for cardiac pacemakers. As a result, battery drain is typically much higher for nerve stimulation applications than for cardiac pacemakers.
- The net result of these factors is that the battery will not last nearly as long as in cardiac pacemakers. Because the indicated patient population is also much younger, the expense and impact of surgical generator replacement will become significant, and detract from the appeal of this therapy. In fact, it has been reported in the medical literature that the battery life can be as short as one and half years for implantable nerve stimulator. (R. S. McLachlan, p. 233).
- There are several other advantages of the present inductively coupled system.
- 5) The hardware components implanted in the body are much less. This is advantageous for the patient in terms of patient comfort, and it decreases the chances of the hardware getting infected in the body. Typically, when an implantable system gets infected in the body, it cannot be easily treated with antibiotics and eventually the whole implanted system has to be explanted.
- 2) Because the power source is external, the physician can use stimulation sequences that are more effective and more demanding on the power supply, such as longer “on” time.
- 3) With the controlling circuitry being external, the physician and the patient may easily select from a number of predetermined programs, override a program, manually operate the device or even modify the predetermined programs.
- 4) The external inductively-coupled nerve stimulation (EINS) system is quicker and easier to implant.
- 5) The external pulse generator does not need to be monitored for “End-of-Life” (EOL) like the implantable system, thus resulting in cost saving and convenience.
- 6) The EINS system can be manufactured at a significantly lower cost of an implantable pulse generator and programmer system, providing the patient and medical establishment with cost effective therapies.
- 7) The EINS system makes it more convenient for the patient or caretaker to turn the device on during an “Aura” that sometimes precedes the seizures. Also, because programming the device is much simpler, the patient or caretaker may reprogram the device at night time by simply pressing one or two buttons to improve patient comfort.
- 8) Occasionally, an individual responds adversely to an implanted medical device and the implanted hardware must be removed. In such a case, a patient having the EINS systems has less implanted hardware to be removed and the cost ofthe pulse generator does not become a factor.
- In the conventional manner of implanting, a cervical incision is made above the clavicle, and another infraclavicular incision is made in the deltapectoral region for the implantable stimulus generator pocket. To tunnel the lead to the cervical incision, a shunt-passing tool is passed from the cervical incision to the generator pocket, where the electrode is attached to the shunt-passing tool and the electrode is then “pulled” back to the cervical incision for attachment to the nerve. This standard technique has the disadvantage that it is time consuming and it tends to create an open space in the subcutaneous tissue. Post surgically the body will fill up this space with serous fluid, which can be undesirable.
- To make the subcutaneous tunneling simpler and to avoid possible complication, one form of the implantable lead body is designed with a hollow lumen to aid in implanting. In this embodiment, a special tunneling tool slides into a hollow lumen. After the cervical and infraclavicular incisions are made, the tunneling tool and lead are simply “pushed” to the cervical incision and the tunneling tool is pulled out. Since the tunneling tool is inside the lead, no extra subcutaneous space is created around the lead, as the lead is pushed. This promotes better healing post-surgically.
- The apparatus and methods disclosed herein also may be appropriate for the treatment of other conditions, as disclosed in co-pending applications filed on Oct. 26, 1998, entitled APPARATUS AND METHOD FOR ADJUNCT (ADD-ON) THERAPY OF DEMENTIA AND ALZHEIMER'S DISEASE UTILIZING AN IMPLANTABLE LEAD AND AN EXTERNAL STIMULATOR and APPARATUS AND METHOD FOR ADJUNCT (ADD-ON) THERAPY FOR PAIN SYNDROMES UTILIZING AN IMPLANTABLE LEAD AND AN EXTERNAL STIMULATOR, the disclosures of which are incorporated herein by reference.
- The apparatus and methodology of this invention generally relates to the adjunct (add-on) treatment of depression, migraine, neuropsychiatric disorders, partial complex epilepsy, generalized epilepsy, and involuntary movement disorders such as in Parkinson's disease. More particularly, the apparatus and methodology in accordance with the invention provides a more adaptable and less intrusive treatment for such conditions. In one embodiment of the invention, the apparatus consists of an easy to implant lead-receiver, an external stimulator containing controlling circuitry and power supply, and an electrode containing a coil for inductively coupling the external pulse generator to the implanted lead-receiver. A separately provided tunneling tool may be used as an aid for implanting the lead-receiver.
- In another embodiment of the invention, the external stimulator has two modes of operation: one with several pre-determined programs that may be selectively locked-out by the manufacturer or physician and another with a manual override.
- In another embodiment of the invention, the implantable lead-receiver is inductively coupled to the external stimulator via a patch electrode containing coil. One feature of this invention is to consistently deliver energy from an external coil to an internal coil in an ambulatory patient. A design of the external patch contains means for compensating for relative movement of the axis of the external and internal coils by deflecting the energy via targets located in the external patch.
- Another feature of this invention is to provide an apparatus to aid in implanting the lead-receiver, including a hollow lumen in the lead body to receive a tunneling tool.
- For the purpose of illustrating the invention, there are shown in accompanying drawing forms which are presently preferred, it being understood that the invention is not intended to be limited to the precise arrangement and instrumentalities shown.
- FIG. 1A is a diagram of the lateral view of brain and spinal cord, with its relationship to the vagus nerve.
- FIG. 1B is a diagram of the base of brain showing the relationship of vagus nerve to the other cranial nerves.
- FIG. 1C is a diagram of brain showing afferent and efferent pathways.
- FIG. 1D is diagram of vagal nerve afferents through the nucleus of the solitary tract.
- FIG. 2A is a diagram showing a patient wearing an external inductively-coupled nerve stimulator (EINS) system.
- FIG. 2B is a diagram showing two coils along their axis, in a configuration such that the mutual inductance would be maximum.
- FIG. 3A is a diagram showing the effects of two coils with axes at right angles.
- FIG. 3B is a diagram showing the effects of two coils with axes at right angles, with a ferrite target included.
- FIG. 4A is a side view of an external patch showing the transmitting coil and targets.
- FIG. 4B is top view of an external patch showing the transmitting coil and targets.
- FIG. 5 is a diagram showing the implanted lead-receiver and the transmitting coil.
- FIG. 6 is a diagram showing the implanted lead-receiver underneath the skin, also showing the relative position of the external coil
- FIG. 7 is a diagram showing the proximal end of the lead-receiver.
- FIG. 8 is a diagram of circuitry within the proximal portion of the implanted lead-receiver.
- FIG. 9 is a diagram of the body of the lead-receiver.
- FIG. 10 is a diagram of a tunneling tool for aiding in the implantation of the lead-receiver.
- FIG. 11 is diagram of another tunneling tool for aiding in the implantation of the lead-receiver.
- FIG. 12 is a diagram of an external patch and external pulse generator.
- FIG. 13 is a prospective view of an external pulse generator.
- FIG. 14 is a flow diagram of the external pulse generator.
- FIG. 15 is a diagram of a hydrogel electrode.
- FIG. 16 is a diagram of a lead-receiver utilizing a fiber electrode at the distal end.
- FIG. 17 is a diagram of a fiber electrode wrapped around Dacron polyester.
- FIG. 18 is a diagram of a lead-receiver with a spiral electrode.
- FIG. 19 is a diagram of an electrode embedded in tissue.
- FIG. 20 is a diagram of an electrode containing steroid drug inside.
- FIG. 21 is a diagram of an electrode containing steroid drug in a silicone collar at the base of electrode.
- FIG. 22 is a diagram of an electrode with steroid drug coated on the surface of the electrode.
- FIG. 23 is a diagram of cross sections of implantable lead-receiver body showing different lumens.
- The following are reference numbers in the drawings:
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
- FIG. 2A shows a schematic diagram of a patient32 with an implantable lead-
receiver 34 and anexternal stimulator 42, clipped on to abelt 44 in this case. Theexternal stimulator 42, may alternatively be placed in a pocket or other carrying device. Anexternal patch electrode 36 provides the coupling between theexternal stimulator 42 and the implantable lead-receiver 34. - The
external stimulator 42 is inductively coupled to the lead-receiver 34. As shown in FIG. 2B, when two coils are arranged with their axes on the same line, current sent throughcoil 46 creates a magnetic field that cutscoil 48 which is placed subcutaneously. Consequently, a voltage will be induced incoil 48 whenever the field strength ofcoil 46 is changing. This induced voltage is similar to the voltage of self-induction but since it appears in the second coil because of current flowing in the first, it is a mutual effect and results from the mutual inductance between the two coils. Since these two coils are coupled, the degree of coupling depends upon the physical spacing between the coils and how they are placed with respect to each other. Maximum coupling exists when they have a common axis and are as close together as possible. The coupling is least when the coils are far apart or are placed so their axes are at right angles. As shown in FIG. 5, thecoil 48 inside the lead-receiver 34 is approximately along the same axis as thecoil 46 in theexternal skin patch 36. - As shown in FIG. 3A, when the axis of transmitting
coil 46 is at right angles to the axis of the receivingcoil 48, a given drivingvoltage 51 results in zerovoltage 53 across the receivingcoil 48. But, as shown in FIG. 3B by addingferrite target 45, a given drivingvoltage 51 through the transmittingcoil 46 results in asignal voltage 55 across thereceiver coil 48. The efficiency is improved by having multiple ferrite targets. An alternate external patch shown in FIGS. 4A and 4B containsmultiple targets 57. FIG. 4A shows a side view of the patch, and FIG. 4B shows a top view of the patch. Havingmultiple targets 57 in theexternal patch 43 compensates for non-alignment of the axis between the transmittingcoil 46 and receivingcoil 48. Since relative rotations between the axis of external transmittingcoil 46 and internal receivingcoil 48 which may occur during breathing, muscle contractions, or other artifacts are compensated for, results in continuous prolonged stimulation. - Referring to FIG. 6, the implantable lead-
receiver 34 looks somewhat like a golf “tee” and is the only implantable portion of the system. The “head” orproximal end 49 contains thecoil 48 and electronic circuitry (hybrid) 98 which is hermetically sealed, and covered with silicone. It also has four anchoringsleeves 130 for tying it to subcutaneous tissue. FIG. 7 is a close-up view of theproximal portion 49 of the lead-receiver 34 containing the circuitry (hybrid) 98. This circuitry is shown schematically in FIG. 8. A coil 48 (preferably approximately 15 turns) is directly connected to thecase 78. Theexternal stimulator 42 andexternal patch 36 transmit the pulsed alternating magnetic field toreceiver 64 whereat the stimulus pulses are detected bycoil 48 and transmitted to the stimulus site (vagus nerve 54). When exposed to the magnetic field oftransmitter 36,coil 48 converts the changing magnetic field into corresponding voltages with alternating polarity between the coil ends. Acapacitor 68 is used to tunecoil 48 to the high-frequency of thetransmitter 36. Thecapacitor 68 increases the sensitivity and the selectivity of thereceiver 64, which is made sensitive to frequencies near the resonant frequency of the tuned circuit and less sensitive to frequencies away from the resonant frequency. Azenor diode 70 in the current path is used for regulation and to allow the current that is produced by the alternating voltage of the coil to pass in one direction only. Acapacitor 72 andresistor 74 filter-out the high-frequency component of the receiver signal and thereby leave a current of the same duration as the burst ofthe high-frequency signal.Capacitor 76 blocks any net direct current to the stimulatingelectrode tip 80, which is made of platinum/iridium (90%-10%). Alternatively, the stimulating electrode can be made of platinum or platinum/iridium in ratio's such as 80% Platinum and 20% Iridium. - The circuit components are soldered in a conventional manner to an upper conductive layer on a printed circuit board. The
case 78 is connected to thecoil 48 and is made of titanium. Thecase 78 also serves as the return electrode (anode). The surface area of the anode exposed to the tissue is much greater than the surface area of the stimulating electrode 80 (cathode). Therefore, the current density at the anode is too low to unduly stimulate tissue that is in contact with the anode. Alternatively, a bipolar mode of stimulation can also be used. In the bipolar mode of stimulation the cathode and anode are in close proximity to each other. - The body of the lead-
receiver 34 is made of medical grade silicone (available from NuSil Technology, Applied silicone or Dow Chemical). Alternatively, thelead body 59 may be made of medical grade polyurethane (PU) of 55 D or higher durometer, such as available from Dow Chemical. Polyurethane is a stiffer material than silicone. Even though silicone is a softer material, which is favorable, it is also a weaker material than PU. Therefore, silicone coated with Teflon (PTFE) is preferred for this application. PTFE coating is available from Alpa Flex, Indianapolis, Ind. - FIG. 9 shows a close-up of the
lead body 59 showing twolumens Lumen 82 is the “working” lumen, containing thecable conductor 65 which connects to the stimulatingelectrode 52. Theother lumen 84 is preferably slightly larger and is for introducing and placing the lead in the body. Alternatively,lumen 84 may havesmall holes 92 punched along the length of the lead. Thesesmall holes 92 will promote fibrotic tissue in-growth to stabilize the lead position and inhibit the lead from migrating. - Silicone in general is not a very slippery material, having a high coefficient of friction. Therefore, a lubricious coating is added to the body of the lead. Such lubricous coating is available from Coating Technologies Inc. (Scotch Plains, N.J.). Since infection still remains a problem in a small percentage of patients, the lead may be coated with antimicrobial coating such as Silver Sulfer Dizene available from STS Biopolymers, Henrietta, N.Y. The lead may also be coated with anti-inflammatory coating.
- The
distal ball electrode 52, shown in FIG. 6 is made of platinum/iridium (90% platinum and 10% iridium). Platinum/iridium electrodes have a long history in cardiac pacing applications. During the distal assembly procedure, thesilicone lead body 59 is first cleaned with alcohol. The conductor cable 65 (available from Lake Region, Minn.) is passed through the “working”lumen 82. The cable is inserted into thedistal electrode 52, and part of the body of electrode is crimped to thecable 65 with a crimper. Alternatively, thecable conductor 65 may be arc welded or laser welded to thedistal electrode 52. The distal end of the insulation is then slided over the crimp such that only the tissue stimulating portion of thedistal electrode 52 is exposed. Following this, a small needle is attached to a syringe filled with medical glue. The needle is inserted into the distal end of insulation, and small amounts of medical glue are injected between the distal end of the insulation anddistal electrode 52. The assembly is then cured in an oven. - As shown in FIGS. 9 and 10, a
tunneling tool 95 is inserted into theempty lumen 84 to push the distal end (containing the cathode electrode 52) towards thevagus nerve 54. Thetunneling tool 95, is comprised of ametal rod 91 and ahandle 88. As shown in FIG. 11, anothertunneling tool 94 with a smaller handle 86 may also be used. Both are available from Popper and Sons, New Hyde Park, N.Y. or Needle Technology. Alternatively, the tunneling tool may be made of strong plastic or other suitable material. - An
external patch electrode 43 for inductive coupling is shown in FIG. 12. One end of the patch electrode contains thecoil 46, and the other end has anadapter 40 to fit into theexternal stimulator 42. Theexternal patch electrode 43, is a modification of the patch electrode available from TruMed Technologies, Burnsville, Minn. - FIG. 13 shows a front view of an
external stimulator 42, which preferably is slightly larger than a conventional pager. Theexternal stimulator 42 contains the circuitry and rechargeable or replaceable power source. Theexternal stimulator 42 has two modes of operation. In the first mode of operation there are several pre-determined programs, preferably up to nine, which differ in stimulus intensity, pulse width, frequency of stimulation, and on-off timing sequence, e.g. “on” for 10 seconds and “off” for 50 seconds in repeating cycles. For patient safety, any number of these programs may be locked-out by the manufacturer or physician. In the second mode, the patient, or caretaker may activate the stimulation on at any time. This mode is useful for epileptic patients that have the characteristic “aura”, which are sensory signs immediately preceding the convulsion that many epileptics have. When the device is turned on, a green light emitting diode (LED) indicates that the device is emitting electrical stimulation. - Pre-determined programs are arranged in such a way that the aggressiveness of the therapy increases from
program # 1 toProgram # 9. Thus the first three programs provide the least aggressive therapy, and the last three programs provide the most aggressive therapy. The following are examples of least aggressive therapy. - Program #1:
- 1.0 mA current output, 0.2 msec pulse width, 15 Hz frequency, 15 sec ON time—1.0 min OFF time, in repeating cycles.
- Program #2:
- 1.5 mA current output, 0.3 msec pulse width, 20 Hz frequency, 20 sec ON time—2.0 min OFF time, in repeating cycles.
- The following are examples of intermediate level of therapy.
- Program #5:
- 2.0 mA current output, 0.2 msec pulse width, 25 Hz frequency, 20 sec ON time—1.0 min OFF time, in repeating cycles.
- Program #6:
- 2.0 mA current output, 0.25 msec pulse width, 25 Hz frequency, 30 sec ON time—1.0 min OFF time, in repeating cycles.
- The following are examples of most aggressive therapy.
- Program #8:
-
- Program #9:
-
- The majority of patients will fall into the category that require an intermediate level of therapy, such as
program # 5. The above are examples of the pre-determined programs that are delivered to the vagus nerve. The actual parameter settings for any given patient may deviate somewhat from the above. - FIG. 14 shows a top level block diagram of the
external stimulator 42. As previously mentioned, there are two modes of stimulation with theexternal stimulator 42. The first mode is a series of pre-determinedstandard programs 71, differing in the aggressiveness of the therapy. The second mode ispatient override 73, where upon pressing a button, the device immediately goes into the active mode. Theselector 69 which comprises ofpre-determined programs 71 andpatient override 73 feeds intoprogrammable control logic 75. Theprogrammable control logic 75 controls thepulse frequency oscillator 79. The output of thepulse frequency oscillator 79 is amplified 83, filtered 87 and provided to the external coil (antenina) 89, which is then transmitted to the implantedreceiver 34 for stimulation of the nerve. Theprogrammable control logic 75 is connected to anindicator 85 showing on-off status, as well as the battery status. Theexternal stimulator 42 is powered by aDC battery 81. Aprogramming station 77 provides the capability to download and change programs if the need arises. - Conventional integrated circuits are used for the logic, control and timing circuits. Conventional bipolar transistors are used in radio-frequency oscillator, pulse amplitude ramp control and power amplifier. A standard voltage regulator is used in low-voltage detector. The hardware and software to deliver these predetermined programs is well known to those skilled in the art.
- The fabrication of the lead-
receiver 34 is designed to be modular. Thus, several different components can be mixed and matched without altering the functionality of the device significantly. As shown in FIG. 6, the lead-receiver 34 components are the proximal end 49 (containingcoil 48,electrical circuitry 98, and case 78), thelead body 59 containing theconductor 65, and the distal electrode (cathode) 52. In the modular design concept, several design variables are possible, as shown in the table below.Table of lead-receiver design variables Proximal Distal End End Circuitry Conductor and Lead Lead body- (connecting Return body- Insulation proximal and Electrode - Electrode - electrode Lumens materials Lead-Coating distal ends) Material Type Bipolar Single Polyurethane Lubricious Alloy of Pure Standard ball (PVP) Nickal-Cobalt Platinum electrode Unipolar Double Silicone Antimicrobial Platinum- Hydrogel Iridium electrode (Pt/Ir) alloy Triple Silicone with Anti- Pt/Ir Spiral Polytetrafluor inflammatory coated with electrode oethylene Titanium (PTFE) Nitride Coaxial Carbon Steroid eluting Fiber electrode - Either silicone or polyurethane is suitable material for this implantable
lead body 59. Both materials have proven to have desirable qualities which are not available in the other. Permanently implantable pacemaker leads made of polyurethane are susceptible to some forms of degradation over time. The identified mechanisms are Environmental Stress Cracking (ESC) and Metal Ion Oxidation (MIO). For this reason silicone material is slightly preferred over polyurethane. - Nerve-electrode interaction is an integral part of the stimulation system. As a practical benefit of modular design, any type of electrode described below can be used as the distal (cathode) stimulating electrode, without changing fabrication methodology or procedure significantly. When a standard ball electrode made of platinum or platinum/iridium is placed next to the nerve, and secured in place, it promotes an inflammatory response that leads to a thin fibrotic sheath around the electrode over a period of 1 to 6 weeks. This in turn leads to a stable position of electrode relative to the nerve, and a stable electrode-tissue interface, resulting in reliable stimulation of the nerve chronically without damaging the nerve.
- Alternatively, other electrode forms that are non-traumatic to the nerve such as hydrogel, platinum fiber, or steroid elution electrodes may be used with this system. The concept of hydrogel electrode for nerve stimulation is shown schematically in FIG. 15. The
hydrogel material 100 is wrapped around thenerve 54, withtiny platinum electrodes 102 being pulled back from nerve. Over a period of time in the body, thehydrogel material 100 will undergo degradation and there will be fibrotic tissue buildup. Because of the softness of thehydrogel material 100, these electrodes are non-traumatic to the nerve. - The concept of platinum fiber electrodes is shown schematically in FIG. 16. The
distal fiber electrode 104 attached to the lead-receiver 34 may be platinum fiber or cable, or the electrode may be thin platinum fiber wrapped around Dacron polyester orPolyimide 106. As shown in FIG. 17, theplatinum fibers 108 may be woven aroundDacron polyester fiber 106 orplatinum fibers 108 may be braided. At implant, thefiber electrode 104 is loosely wrapped around the surgically isolated nerve, then tied loosely so as not to constrict the nerve or put pressure on the nerve. As a further extension, the fiber electrode may be incorporated into aspiral electrode 105 as is shown schematically in FIG. 18. Thefiber electrode 110 is on the inner side of polyurethane orsilicone insulation 112 which is heat treated to retain its spiral shape. - Alternatively, steroid elution electrodes may be used. After implantation of a lead in the body, during the first few weeks there is buildup of fibrotic tissue in-growth over the electrode and to some extent around the lead body. This fibrosis is the end result of body's inflammatory response process which begins soon after the device is implanted. The fibrotic tissue sheath has the net effect of increasing the distance between the stimulation electrode (cathode) and the excitable tissue, which is the vagal nerve in this case. This is shown schematically in FIG. 19, where
electrode 52 when covered with fibrotic tissue becomes the “virtual”electrode 114. Non-excitable tissue is depicted as 120 and excitable tissue as 118. A small amount of corticosteroid, dexamethasone sodium phosphate commonly referred to as “steroid” or “dexamethasone” placed inside or around the electrode, has significant beneficial effect on the current or energy threshold, i.e. the amount of energy required to stimulate the excitable tissue. This is well known to those familiar in the art, as there is a long history of steroid elution leads in cardiac pacing application. It takes only about 1 mg of dexamethasone to produce the desirable effects. Three separate ways of delivering the steroid drug to the electrode nerve-tissue interface are being disclosed here. Dexamethasone can be placed inside an electrode with microholes, it can be placed adjacent to the electrode in a silicone collar, or it can be coated on the electrode itself. - Dexamethasone inside the stimulating electrode is shown schematically in FIG. 20. A silicone core that is impregnated with a small quantity of
dexamethasone 121, is incorporated inside the electrode. The electrode tip is depicted as 124 and electrode body as 122. Once the lead is implanted in the body, thesteroid 121 elutes out through the small holes in the electrode. The steroid drug then has anti-inflammatory action at the electrode tissue interface, which leads to a much thinner fibrotic tissue capsule. - Another way of having a steroid eluting nerve stimulating electrode, is to have the steroid agent placed outside the
distal electrode 52 in asilicone collar 126. This is shown schematically in FIG. 21. Approximately 1 mg of dexamethasone is contained in asilicone collar 126, at the base of thedistal electrode 52. With such a method, the steroid drug elutes around theelectrode 52 in a similar fashion and with similar pharmacokinetic properties, as with the steroid drug being inside the electrode. - Another method of steroid elution for nerve stimulation electrodes is by coating of steroid on the outside (exposed) surface area of the electrode. This is shown schematically in FIG. 22. Nafion is used as the coating matrix. Steroid membrane coating on the outside of the electrode is depicted as128. The advantages of this method are that it can easily be applied to any electrode, fast and easy manufacturing, and it is cost effective. With this method, the rate of steroid delivery can be controlled by the level of sulfonation.
- A schematic representation of the cross section of different possible lumens is shown in FIG. 23. The
lead body 59 can have one, two, or three lumens for conducting cable, with or without a hollow lumen. In the cross sections, 132A-F represents lumens(s) for conducting cable, and 134A-C represents hollow lumen for aid in implanting the lead. - Additionally, different classes of coating may be applied to the implantable lead-
receiver 34 after fabrication. These coatings fall into three categories, lubricious coating, antimicrobial coating, and anti-inflammatory coating. - The advantage of modular fabrication is that with one technology platform, several derivative products or models can be manufactured. As a specific practical example, using a silicone lead body platform, three separate derivative or lead models can be manufactured by using three different electrodes such as standard electrode, steroid electrode or spiral electrode. This is made possible by designing the fabrication steps such that the distal electrodes are assembled at the end, and as long as the electrodes are mated to the insulation and conducting cable, the shape or type of electrode does not matter. Similarly, different models can be produced by taking a finished lead and then coating it with lubricious coating or antimicrobial coating. In fact, considering the design variables disclosed in table 1, a large number of combinations are possible. Of these large number of possible combinations, about 6 or 7 models are planned for manufacturing. These include lead body composed of silicone and PTFE with standard ball electrodes made of platinum/iridium alloy, and silicone lead body with spiral electrode.
- In addition to the neuromodulation of a cranial nerve such as the vagus nerve described above, neuromodulation of other nerves in the body can be performed. For example, neuromodulation of sacral nerve, which has beneficial effects for urinary incontinance, can be performed using an implantable lead-receiver and an external stimulator containing predetermined program, where the two are inductively coupled. In such a case, the secondary coil wold be implanted in the lower abdominal region.
- While various embodiments of the present invention have been described in detail, it is apparent that modifications and adaptations of those embodiments will occur to those skilled in the art. However, it is to be expressly understood that such modifications and adaptations are within the spirit and scope of the present invention.
Claims (24)
1. An apparatus for electrical stimulation therapy for treatment of at least one of depression, migraine and neuropsychiatric disorders comprising:
a) an implantable lead-receiver comprising a secondary coil and at least one electrode capable of stimulating a cranial nerve;
b) an external stimulator comprising a power source, circuitry to emit electrical signals, at least two predetermined programs to control said electrical signals, and a primary coil;
c) said primary coil of said external stimulator and said secondary coil of said implantable lead-receiver being capable of forming an electrical connection by inductive coupling,
whereby said external stimulator is capable of controlling the stimulation of said cranial nerve.
2. The apparatus of wherein said neuropsychiatric disorder comprises obsessive compulsive disorders.
claim 1
3. The apparatus of , wherein said cranial nerve is the left vagus nerve.
claim 1
4. The apparatus of , wherein said external stimulator comprises a patient override mechanism to manually activate said external stimulator.
claim 1
5. The apparatus of , wherein said predetermined programs are capable of being modified to modify said electrical signals.
claim 1
6. The apparatus of , further comprising a program selection mechanism wherein said at least two predetermined programs may be selectively operated.
claim 1
7. The apparatus of , wherein said primary coil of said external stimulator is adapted to be in contact with the skin of the patient.
claim 1
8. The apparatus of , wherein said lead-receiver comprises a lead body with at least one lumen, a lead body insulation, a conductor, at least one electrode and a coil.
claim 1
9. The apparatus of , wherein said at least one lumen is selected from the group consisting of single, double, triple and coaxial lumens.
claim 8
10. The apparatus of wherein said lead body insulation is selected from the group consisting of polyurethane, silicone and silicone with polytetrafluoroethylene.
claim 8
11. The apparatus of wherein said lead body further comprises a coating selected from the group consisting of lubricious PVP, antimicrobial and anti-inflammatory coatings.
claim 8
12. The apparatus of wherein said electrode comprises amaterial selected from the group consisting of platinum, platinum/iridium alloy, platinum/iridium alloy coated with titanium nitride and carbon.
claim 8
13. The apparatus of wherein said electrode is selected from the group consisting of standard ball electrodes, hydrogel electrodes, spiral electrodes, steroid eluting electrodes, and fiber electrodes.
claim 8
14. The apparatus of , wherein said electrical signals comprise at least one variable component selected from the group consisting of the current amplitude, pulse width, frequency and on-off timing sequence, and said at least two predetermined programs controls said variable component of said electrical signals.
claim 1
15. A method to provide therapy for at least one of depression, migraine and neuropsychiatric disorders, comprising;
a) providing an implantable lead-receiver comprising a secondary coil and at least one electrode to stimulate a cranial nerve;
b) providing an external stimulator comprising circuitry to emit electrical signals, at least two programs to control said electrical signals, an external coil and a power supply;
c) activating one of said at least two programs of said external stimulator to emit said electrical signals to said external coil;
d) inductively transferring said electrical signals from said external coil of said external stimulator to said secondary coil of said lead-receiver;
whereby said electrical signals stimulate said cranial nerve according to at least one of said at least two predetermined programs.
16. The method of , wherein said cranial nerve is the left vagus nerve.
claim 15
17. The method of , wherein said cranial nerve is stimulated by bipolar stimulation.
claim 15
18. The method of , wherein said cranial nerve is stimulated by unipolar stimulation.
claim 15
19. The method of , wherein the step of activating one of said at least two predetermined programs is manually performed.
claim 15
20. The method of , further comprising manually controlling said electrical signals to stimulate said cranial nerve.
claim 15
21. The method of , wherein
claim 15
a) said electrical signals comprise at least one variable component selected from the group consisting of the current amplitude, pulse width, frequency, and on-off timing sequence; and
b) said at least two predetermined programs controls said variable component of said electrical signals.
22. The method of , further comprising manually disengaging said at least two predetermined programs.
claim 15
23. A method for treating symptoms of depression, migraine or neuropsychiatric disorders comprising:
a) selecting a predetermined program to control the output of an external stimulator;
b) activating said external stimulator to emit electrical signals in accordance with said predetermined program; and
c) inductively coupling said external stimulator with an implantable lead-receiver to stimulate a cranial nerve.
24. The method of , further comprising implanting beneath the skin of a patient said lead-receiver in direct electrical contact with said cranial nerve.
claim 21
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/727,570 US6356788B2 (en) | 1998-10-26 | 2000-11-30 | Apparatus and method for adjunct (add-on) therapy for depression, migraine, neuropsychiatric disorders, partial complex epilepsy, generalized epilepsy and involuntary movement disorders utilizing an external stimulator |
US09/837,661 US6611715B1 (en) | 1998-10-26 | 2001-04-19 | Apparatus and method for neuromodulation therapy for obesity and compulsive eating disorders using an implantable lead-receiver and an external stimulator |
US09/837,660 US6615081B1 (en) | 1998-10-26 | 2001-04-19 | Apparatus and method for adjunct (add-on) treatment of diabetes by neuromodulation with an external stimulator |
US09/837,662 US6564102B1 (en) | 1998-10-26 | 2001-04-19 | Apparatus and method for adjunct (add-on) treatment of coma and traumatic brain injury with neuromodulation using an external stimulator |
US09/837,512 US6668191B1 (en) | 1998-10-26 | 2001-04-19 | Apparatus and method for electrical stimulation adjunct (add-on) therapy of atrial fibrillation, inappropriate sinus tachycardia, and refractory hypertension with an external stimulator |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/178,060 US6205359B1 (en) | 1998-10-26 | 1998-10-26 | Apparatus and method for adjunct (add-on) therapy of partial complex epilepsy, generalized epilepsy and involuntary movement disorders utilizing an external stimulator |
US09/727,570 US6356788B2 (en) | 1998-10-26 | 2000-11-30 | Apparatus and method for adjunct (add-on) therapy for depression, migraine, neuropsychiatric disorders, partial complex epilepsy, generalized epilepsy and involuntary movement disorders utilizing an external stimulator |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/178,060 Continuation-In-Part US6205359B1 (en) | 1998-10-26 | 1998-10-26 | Apparatus and method for adjunct (add-on) therapy of partial complex epilepsy, generalized epilepsy and involuntary movement disorders utilizing an external stimulator |
Related Child Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/837,660 Continuation-In-Part US6615081B1 (en) | 1998-10-26 | 2001-04-19 | Apparatus and method for adjunct (add-on) treatment of diabetes by neuromodulation with an external stimulator |
US09/837,661 Continuation-In-Part US6611715B1 (en) | 1998-10-26 | 2001-04-19 | Apparatus and method for neuromodulation therapy for obesity and compulsive eating disorders using an implantable lead-receiver and an external stimulator |
US09/837,512 Continuation-In-Part US6668191B1 (en) | 1998-10-26 | 2001-04-19 | Apparatus and method for electrical stimulation adjunct (add-on) therapy of atrial fibrillation, inappropriate sinus tachycardia, and refractory hypertension with an external stimulator |
US09/837,662 Continuation-In-Part US6564102B1 (en) | 1998-10-26 | 2001-04-19 | Apparatus and method for adjunct (add-on) treatment of coma and traumatic brain injury with neuromodulation using an external stimulator |
Publications (2)
Publication Number | Publication Date |
---|---|
US20010003799A1 true US20010003799A1 (en) | 2001-06-14 |
US6356788B2 US6356788B2 (en) | 2002-03-12 |
Family
ID=26873918
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/727,570 Expired - Fee Related US6356788B2 (en) | 1998-10-26 | 2000-11-30 | Apparatus and method for adjunct (add-on) therapy for depression, migraine, neuropsychiatric disorders, partial complex epilepsy, generalized epilepsy and involuntary movement disorders utilizing an external stimulator |
Country Status (1)
Country | Link |
---|---|
US (1) | US6356788B2 (en) |
Cited By (95)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020062060A1 (en) * | 1998-10-06 | 2002-05-23 | Yossi Gross | Incontinence treatment device |
US20030082884A1 (en) * | 2001-10-26 | 2003-05-01 | International Business Machine Corporation And Kabushiki Kaisha Toshiba | Method of forming low-leakage dielectric layer |
US20030083698A1 (en) * | 2001-11-01 | 2003-05-01 | Whitehurst Todd K. | Thrombolysis and chronic anticoagulation therapy |
US20030171789A1 (en) * | 2001-11-01 | 2003-09-11 | Medtronic, Inc. | Method and apparatus for programming an implantable medical device |
US20030236557A1 (en) * | 2002-06-20 | 2003-12-25 | Whitehurst Todd K. | Cavernous nerve stimulation via unidirectional propagation of action potentials |
US20030236558A1 (en) * | 2002-06-20 | 2003-12-25 | Whitehurst Todd K. | Vagus nerve stimulation via unidirectional propagation of action potentials |
US20040015204A1 (en) * | 2002-06-20 | 2004-01-22 | Whitehurst Todd K. | Implantable microstimulators and methods for unidirectional propagation of action potentials |
US20040015205A1 (en) * | 2002-06-20 | 2004-01-22 | Whitehurst Todd K. | Implantable microstimulators with programmable multielectrode configuration and uses thereof |
US20040243205A1 (en) * | 2003-05-30 | 2004-12-02 | Medtronic, Inc. | Implantable cortical neural lead and method |
US20050027158A1 (en) * | 2002-10-21 | 2005-02-03 | Becker Paul F. | Method and apparatus for the treatment of physical and mental disorders with low frequency, low flux density magnetic fields |
US20050049651A1 (en) * | 2000-06-20 | 2005-03-03 | Whitehurst Todd K. | Treatment of mood and/or anxiety disorders by electrical brain stimulation and/or drug infusion |
US20050049650A1 (en) * | 2000-10-30 | 2005-03-03 | Medtronic, Inc. | Method for treating obsessive-compulsive disorder with electrical stimulation of the brain internal capsule |
WO2005039693A1 (en) * | 2003-10-27 | 2005-05-06 | Jorge Alberto Morales Sanchez | Device for emitting electric impulses directed to the brain |
US20050182287A1 (en) * | 2002-10-21 | 2005-08-18 | Becker Paul F. | Method and apparatus for the treatment of physical and mental disorders with low frequency, low flux density magnetic fields |
US20050182467A1 (en) * | 2003-11-20 | 2005-08-18 | Angiotech International Ag | Electrical devices and anti-scarring agents |
US20050209652A1 (en) * | 2001-04-26 | 2005-09-22 | Whitehurst Todd K | Methods and systems for electrical and/or drug stimulation as a therapy for erectile dysfunction |
US20050240229A1 (en) * | 2001-04-26 | 2005-10-27 | Whitehurst Tood K | Methods and systems for stimulation as a therapy for erectile dysfunction |
US20050251212A1 (en) * | 2000-09-27 | 2005-11-10 | Cvrx, Inc. | Stimulus regimens for cardiovascular reflex control |
US20060025829A1 (en) * | 2004-07-28 | 2006-02-02 | Armstrong Randolph K | Power supply monitoring for an implantable device |
US20060052838A1 (en) * | 2004-09-08 | 2006-03-09 | Kim Daniel H | Methods of neurostimulating targeted neural tissue |
US20060111626A1 (en) * | 2003-03-27 | 2006-05-25 | Cvrx, Inc. | Electrode structures having anti-inflammatory properties and methods of use |
US20060161219A1 (en) * | 2003-11-20 | 2006-07-20 | Advanced Neuromodulation Systems, Inc. | Electrical stimulation system and method for stimulating multiple locations of target nerve tissue in the brain to treat multiple conditions in the body |
US20060206163A1 (en) * | 2005-03-11 | 2006-09-14 | Wahlstrand Carl D | Neurostimulation site screening |
US20060206162A1 (en) * | 2005-03-11 | 2006-09-14 | Wahlstrand Carl D | Implantable neurostimulator device |
US20060229688A1 (en) * | 2005-04-08 | 2006-10-12 | Mcclure Kelly H | Controlling stimulation parameters of implanted tissue stimulators |
US20060258950A1 (en) * | 2002-02-04 | 2006-11-16 | Synergistic Neurotherapy Adjustment Process, Inc. (Trade At Synaps) | Method and apparatus for utilizing amplitude-modulated pulse-width modulation signals for neurostimulation and treatment of neurological disorders using electrical stimulation |
US20060280655A1 (en) * | 2005-06-08 | 2006-12-14 | California Institute Of Technology | Intravascular diagnostic and therapeutic sampling device |
US7151961B1 (en) * | 2002-05-24 | 2006-12-19 | Advanced Bionics Corporation | Treatment of movement disorders by brain stimulation |
US20070021790A1 (en) * | 2000-09-27 | 2007-01-25 | Cvrx, Inc. | Automatic baroreflex modulation responsive to adverse event |
US20070027504A1 (en) * | 2005-07-27 | 2007-02-01 | Cyberonics, Inc. | Cranial nerve stimulation to treat a hearing disorder |
US20070118183A1 (en) * | 2005-11-18 | 2007-05-24 | Mark Gelfand | System and method to modulate phrenic nerve to prevent sleep apnea |
US20070123938A1 (en) * | 2005-11-30 | 2007-05-31 | Haller Matthew I | Magnetically coupled microstimulators |
US20070260288A1 (en) * | 2006-03-03 | 2007-11-08 | Yossi Gross | Apparatus for treating stress and urge incontinence |
US20080015642A1 (en) * | 2006-07-17 | 2008-01-17 | Sherwood Services Ag | Method for stimulation of the vagus nerve |
US20080097142A1 (en) * | 2006-10-20 | 2008-04-24 | Paul Savage | Magnetic field generator, method of generating a pulsed sinusoidal magnetic wave and magnetic field generator system |
US20080177350A1 (en) * | 2000-09-27 | 2008-07-24 | Cvrx, Inc. | Expandable Stimulation Electrode with Integrated Pressure Sensor and Methods Related Thereto |
US20080208282A1 (en) * | 2007-01-22 | 2008-08-28 | Mark Gelfand | Device and method for the treatment of breathing disorders and cardiac disorders |
US20090112962A1 (en) * | 2007-10-31 | 2009-04-30 | Research In Motion Limited | Modular squaring in binary field arithmetic |
US20090112282A1 (en) * | 2007-10-26 | 2009-04-30 | Medtronic, Inc. | Occipital nerve stimulation |
US7570999B2 (en) | 2005-12-20 | 2009-08-04 | Cardiac Pacemakers, Inc. | Implantable device for treating epilepsy and cardiac rhythm disorders |
US7627383B2 (en) | 2005-03-15 | 2009-12-01 | Boston Scientific Neuromodulation Corporation | Implantable stimulator |
US20100030227A1 (en) * | 2008-07-31 | 2010-02-04 | Medtronic, Inc. | Medical lead implantation |
US7734355B2 (en) | 2001-08-31 | 2010-06-08 | Bio Control Medical (B.C.M.) Ltd. | Treatment of disorders by unidirectional nerve stimulation |
US20100217340A1 (en) * | 2009-02-23 | 2010-08-26 | Ams Research Corporation | Implantable Medical Device Connector System |
US7801600B1 (en) | 2005-05-26 | 2010-09-21 | Boston Scientific Neuromodulation Corporation | Controlling charge flow in the electrical stimulation of tissue |
US7803148B2 (en) | 2006-06-09 | 2010-09-28 | Neurosystec Corporation | Flow-induced delivery from a drug mass |
US7865243B1 (en) | 2000-04-07 | 2011-01-04 | Boston Scientific Neuromodulation Corporation | Device and therapy for erectile dysfunction and other sexual dysfunction |
US7877136B1 (en) | 2007-09-28 | 2011-01-25 | Boston Scientific Neuromodulation Corporation | Enhancement of neural signal transmission through damaged neural tissue via hyperpolarizing electrical stimulation current |
US20110060380A1 (en) * | 2009-09-10 | 2011-03-10 | Mark Gelfand | Respiratory rectification |
US20110077579A1 (en) * | 2005-03-24 | 2011-03-31 | Harrison William V | Cochlear implant with localized fluid transport |
US7949400B2 (en) | 2000-09-27 | 2011-05-24 | Cvrx, Inc. | Devices and methods for cardiovascular reflex control via coupled electrodes |
US20110295332A1 (en) * | 2010-05-26 | 2011-12-01 | Flint Hills Scientific, L.L.C. | Quantitative multivariate analysis of seizures |
US8160710B2 (en) | 2006-07-10 | 2012-04-17 | Ams Research Corporation | Systems and methods for implanting tissue stimulation electrodes in the pelvic region |
US20120184801A1 (en) * | 2009-03-20 | 2012-07-19 | ElectroCore, LLC | Nerve stimulation methods for averting imminent onset or episode of a disease |
US20120185020A1 (en) * | 2009-03-20 | 2012-07-19 | ElectroCore, LLC. | Nerve stimulation methods for averting imminent onset or episode of a disease |
US8380312B2 (en) | 2009-12-31 | 2013-02-19 | Ams Research Corporation | Multi-zone stimulation implant system and method |
US8380318B2 (en) | 2009-03-24 | 2013-02-19 | Spinal Modulation, Inc. | Pain management with stimulation subthreshold to paresthesia |
US20130066395A1 (en) * | 2009-03-20 | 2013-03-14 | ElectroCore, LLC. | Nerve stimulation methods for averting imminent onset or episode of a disease |
US8433412B1 (en) | 2008-02-07 | 2013-04-30 | Respicardia, Inc. | Muscle and nerve stimulation |
US8518092B2 (en) | 2006-12-06 | 2013-08-27 | Spinal Modulation, Inc. | Hard tissue anchors and delivery devices |
US20130245486A1 (en) * | 2009-03-20 | 2013-09-19 | ElectroCore, LLC. | Devices and methods for monitoring non-invasive vagus nerve stimulation |
US8571651B2 (en) | 2006-09-07 | 2013-10-29 | Bio Control Medical (B.C.M.) Ltd. | Techniques for reducing pain associated with nerve stimulation |
US8571653B2 (en) | 2001-08-31 | 2013-10-29 | Bio Control Medical (B.C.M.) Ltd. | Nerve stimulation techniques |
US8606359B2 (en) | 2000-09-27 | 2013-12-10 | Cvrx, Inc. | System and method for sustained baroreflex stimulation |
GB2504196A (en) * | 2012-06-01 | 2014-01-22 | Bioinduction Ltd | Precision delivery of electrical therapy |
US8774942B2 (en) | 2007-07-10 | 2014-07-08 | Ams Research Corporation | Tissue anchor |
US8805494B2 (en) | 2005-05-10 | 2014-08-12 | Cardiac Pacemakers, Inc. | System and method to deliver therapy in presence of another therapy |
US8983624B2 (en) | 2006-12-06 | 2015-03-17 | Spinal Modulation, Inc. | Delivery devices, systems and methods for stimulating nerve tissue on multiple spinal levels |
US9044592B2 (en) | 2007-01-29 | 2015-06-02 | Spinal Modulation, Inc. | Sutureless lead retention features |
US9056197B2 (en) | 2008-10-27 | 2015-06-16 | Spinal Modulation, Inc. | Selective stimulation systems and signal parameters for medical conditions |
US9205261B2 (en) | 2004-09-08 | 2015-12-08 | The Board Of Trustees Of The Leland Stanford Junior University | Neurostimulation methods and systems |
US9220887B2 (en) | 2011-06-09 | 2015-12-29 | Astora Women's Health LLC | Electrode lead including a deployable tissue anchor |
US9259569B2 (en) | 2009-05-15 | 2016-02-16 | Daniel M. Brounstein | Methods, systems and devices for neuromodulating spinal anatomy |
US9314618B2 (en) | 2006-12-06 | 2016-04-19 | Spinal Modulation, Inc. | Implantable flexible circuit leads and methods of use |
US9327110B2 (en) | 2009-10-27 | 2016-05-03 | St. Jude Medical Luxembourg Holdings SMI S.A.R.L. (“SJM LUX SMI”) | Devices, systems and methods for the targeted treatment of movement disorders |
US9370660B2 (en) | 2013-03-29 | 2016-06-21 | Rainbow Medical Ltd. | Independently-controlled bidirectional nerve stimulation |
US9427573B2 (en) | 2007-07-10 | 2016-08-30 | Astora Women's Health, Llc | Deployable electrode lead anchor |
US9427570B2 (en) | 2006-12-06 | 2016-08-30 | St. Jude Medical Luxembourg Holdings SMI S.A.R.L. (“SJM LUX SMI”) | Expandable stimulation leads and methods of use |
US9486633B2 (en) | 2004-09-08 | 2016-11-08 | The Board Of Trustees Of The Leland Stanford Junior University | Selective stimulation to modulate the sympathetic nervous system |
US9539433B1 (en) | 2009-03-18 | 2017-01-10 | Astora Women's Health, Llc | Electrode implantation in a pelvic floor muscular structure |
US9616234B2 (en) | 2002-05-03 | 2017-04-11 | Trustees Of Boston University | System and method for neuro-stimulation |
US9731112B2 (en) | 2011-09-08 | 2017-08-15 | Paul J. Gindele | Implantable electrode assembly |
US9782584B2 (en) | 2014-06-13 | 2017-10-10 | Nervana, LLC | Transcutaneous electrostimulator and methods for electric stimulation |
US9987488B1 (en) | 2007-06-27 | 2018-06-05 | Respicardia, Inc. | Detecting and treating disordered breathing |
US10105540B2 (en) | 2015-11-09 | 2018-10-23 | Bluewind Medical Ltd. | Optimization of application of current |
US10130809B2 (en) | 2014-06-13 | 2018-11-20 | Nervana, LLC | Transcutaneous electrostimulator and methods for electric stimulation |
US20190134386A1 (en) * | 2017-11-06 | 2019-05-09 | University Of Cincinnati | Transcutaneous spinal cord stimulation for treatment of psychiatric disorders |
US10406366B2 (en) | 2006-11-17 | 2019-09-10 | Respicardia, Inc. | Transvenous phrenic nerve stimulation system |
US11273283B2 (en) | 2017-12-31 | 2022-03-15 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement to enhance emotional response |
US11364361B2 (en) | 2018-04-20 | 2022-06-21 | Neuroenhancement Lab, LLC | System and method for inducing sleep by transplanting mental states |
US11413451B2 (en) | 2010-05-10 | 2022-08-16 | St. Jude Medical Luxembourg Holdings SMI S.A.R.L. (“SJM LUX SMI”) | Methods, systems and devices for reducing migration |
US11452839B2 (en) | 2018-09-14 | 2022-09-27 | Neuroenhancement Lab, LLC | System and method of improving sleep |
US11717686B2 (en) | 2017-12-04 | 2023-08-08 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement to facilitate learning and performance |
US11723579B2 (en) | 2017-09-19 | 2023-08-15 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement |
EP4257180A3 (en) * | 2018-01-18 | 2023-12-20 | Pulsar Medtech Ltd. | External electronic patch for accelerating bone healing or regeneration after trauma |
Families Citing this family (175)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7799337B2 (en) | 1997-07-21 | 2010-09-21 | Levin Bruce H | Method for directed intranasal administration of a composition |
US9375573B2 (en) | 1998-08-05 | 2016-06-28 | Cyberonics, Inc. | Systems and methods for monitoring a patient's neurological disease state |
US9042988B2 (en) | 1998-08-05 | 2015-05-26 | Cyberonics, Inc. | Closed-loop vagus nerve stimulation |
US8762065B2 (en) * | 1998-08-05 | 2014-06-24 | Cyberonics, Inc. | Closed-loop feedback-driven neuromodulation |
US7277758B2 (en) * | 1998-08-05 | 2007-10-02 | Neurovista Corporation | Methods and systems for predicting future symptomatology in a patient suffering from a neurological or psychiatric disorder |
US7403820B2 (en) * | 1998-08-05 | 2008-07-22 | Neurovista Corporation | Closed-loop feedback-driven neuromodulation |
US7209787B2 (en) * | 1998-08-05 | 2007-04-24 | Bioneuronics Corporation | Apparatus and method for closed-loop intracranial stimulation for optimal control of neurological disease |
US9113801B2 (en) * | 1998-08-05 | 2015-08-25 | Cyberonics, Inc. | Methods and systems for continuous EEG monitoring |
US7747325B2 (en) * | 1998-08-05 | 2010-06-29 | Neurovista Corporation | Systems and methods for monitoring a patient's neurological disease state |
US9415222B2 (en) | 1998-08-05 | 2016-08-16 | Cyberonics, Inc. | Monitoring an epilepsy disease state with a supervisory module |
US6269270B1 (en) * | 1998-10-26 | 2001-07-31 | Birinder Bob Boveja | Apparatus and method for adjunct (add-on) therapy of Dementia and Alzheimer's disease utilizing an implantable lead and external stimulator |
US7076307B2 (en) * | 2002-05-09 | 2006-07-11 | Boveja Birinder R | Method and system for modulating the vagus nerve (10th cranial nerve) with electrical pulses using implanted and external components, to provide therapy neurological and neuropsychiatric disorders |
US8914114B2 (en) | 2000-05-23 | 2014-12-16 | The Feinstein Institute For Medical Research | Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation |
US7493172B2 (en) * | 2001-01-30 | 2009-02-17 | Boston Scientific Neuromodulation Corp. | Methods and systems for stimulating a nerve originating in an upper cervical spine area to treat a medical condition |
US7167751B1 (en) | 2001-03-01 | 2007-01-23 | Advanced Bionics Corporation | Method of using a fully implantable miniature neurostimulator for vagus nerve stimulation |
US6892098B2 (en) * | 2001-04-26 | 2005-05-10 | Biocontrol Medical Ltd. | Nerve stimulation for treating spasticity, tremor, muscle weakness, and other motor disorders |
US6622047B2 (en) * | 2001-07-28 | 2003-09-16 | Cyberonics, Inc. | Treatment of neuropsychiatric disorders by near-diaphragmatic nerve stimulation |
US6626680B2 (en) * | 2001-08-24 | 2003-09-30 | Wilson Greatbatch Ltd. | Wire bonding surface |
US20040048795A1 (en) * | 2002-02-26 | 2004-03-11 | North Shore-Long Island Jewish Research Institute | Inhibition of inflammatory cytokine production by stimulation of brain muscarinic receptors |
US20060079936A1 (en) * | 2003-05-11 | 2006-04-13 | Boveja Birinder R | Method and system for altering regional cerebral blood flow (rCBF) by providing complex and/or rectangular electrical pulses to vagus nerve(s), to provide therapy for depression and other medical disorders |
US20070067004A1 (en) * | 2002-05-09 | 2007-03-22 | Boveja Birinder R | Methods and systems for modulating the vagus nerve (10th cranial nerve) to provide therapy for neurological, and neuropsychiatric disorders |
US20050216070A1 (en) * | 2002-05-09 | 2005-09-29 | Boveja Birinder R | Method and system for providing therapy for migraine/chronic headache by providing electrical pulses to vagus nerve(s) |
US20050165458A1 (en) * | 2002-05-09 | 2005-07-28 | Boveja Birinder R. | Method and system to provide therapy for depression using electroconvulsive therapy(ECT) and pulsed electrical stimulation to vagus nerve(s) |
US20060009815A1 (en) * | 2002-05-09 | 2006-01-12 | Boveja Birinder R | Method and system to provide therapy or alleviate symptoms of involuntary movement disorders by providing complex and/or rectangular electrical pulses to vagus nerve(s) |
US20050154426A1 (en) * | 2002-05-09 | 2005-07-14 | Boveja Birinder R. | Method and system for providing therapy for neuropsychiatric and neurological disorders utilizing transcranical magnetic stimulation and pulsed electrical vagus nerve(s) stimulation |
US20050209654A1 (en) * | 2002-05-09 | 2005-09-22 | Boveja Birinder R | Method and system for providing adjunct (add-on) therapy for depression, anxiety and obsessive-compulsive disorders by providing electrical pulses to vagus nerve(s) |
US20050182453A1 (en) * | 2002-05-24 | 2005-08-18 | Whitehurst Todd K. | Treatment of epilepsy by high frequency electrical stimulation and/or drug stimulation |
WO2004034885A2 (en) * | 2002-10-15 | 2004-04-29 | Medtronic Inc. | Signal quality monitoring and control for a medical device system |
WO2004036376A2 (en) | 2002-10-15 | 2004-04-29 | Medtronic Inc. | Multi-modal operation of a medical device system |
EP1562674A4 (en) * | 2002-10-15 | 2008-10-08 | Medtronic Inc | Control of treatment therapy during start-up and during operation of a medical device system |
ATE537748T1 (en) * | 2002-10-15 | 2012-01-15 | Medtronic Inc | MEDICAL DEVICE SYSTEM FOR EVALUATION OF MEASURED NEUROLOGICAL EVENTS |
US7149572B2 (en) * | 2002-10-15 | 2006-12-12 | Medtronic, Inc. | Phase shifting of neurological signals in a medical device system |
WO2004036377A2 (en) * | 2002-10-15 | 2004-04-29 | Medtronic Inc. | Configuring and testing treatment therapy parameters for a medical device system |
AU2003301255A1 (en) | 2002-10-15 | 2004-05-04 | Medtronic Inc. | Screening techniques for management of a nervous system disorder |
US8738136B2 (en) * | 2002-10-15 | 2014-05-27 | Medtronic, Inc. | Clustering of recorded patient neurological activity to determine length of a neurological event |
US7189204B2 (en) * | 2002-12-04 | 2007-03-13 | Cardiac Pacemakers, Inc. | Sleep detection using an adjustable threshold |
WO2004064918A1 (en) * | 2003-01-14 | 2004-08-05 | Department Of Veterans Affairs, Office Of General Counsel | Cervical wagal stimulation induced weight loss |
JP2006519229A (en) * | 2003-02-13 | 2006-08-24 | アルバート・アインシュタイン・カレッジ・オヴ・メディシン・オヴ・イェシヴァ・ユニヴァーシティ | Regulation of food intake and glucose production by modulation of long-chain fatty acyl-CoA levels in the hypothalamus |
US7155279B2 (en) | 2003-03-28 | 2006-12-26 | Advanced Bionics Corporation | Treatment of movement disorders with drug therapy |
US20040225335A1 (en) * | 2003-05-08 | 2004-11-11 | Whitehurst Todd K. | Treatment of Huntington's disease by brain stimulation |
US20050187590A1 (en) * | 2003-05-11 | 2005-08-25 | Boveja Birinder R. | Method and system for providing therapy for autism by providing electrical pulses to the vagus nerve(s) |
US20060074450A1 (en) * | 2003-05-11 | 2006-04-06 | Boveja Birinder R | System for providing electrical pulses to nerve and/or muscle using an implanted stimulator |
US20050197678A1 (en) * | 2003-05-11 | 2005-09-08 | Boveja Birinder R. | Method and system for providing therapy for Alzheimer's disease and dementia by providing electrical pulses to vagus nerve(s) |
US7444184B2 (en) * | 2003-05-11 | 2008-10-28 | Neuro And Cardial Technologies, Llc | Method and system for providing therapy for bulimia/eating disorders by providing electrical pulses to vagus nerve(s) |
US8606356B2 (en) | 2003-09-18 | 2013-12-10 | Cardiac Pacemakers, Inc. | Autonomic arousal detection system and method |
US9050469B1 (en) | 2003-11-26 | 2015-06-09 | Flint Hills Scientific, Llc | Method and system for logging quantitative seizure information and assessing efficacy of therapy using cardiac signals |
US7769461B2 (en) * | 2003-12-19 | 2010-08-03 | Boston Scientific Neuromodulation Corporation | Skull-mounted electrical stimulation system and method for treating patients |
US7422555B2 (en) * | 2003-12-30 | 2008-09-09 | Jacob Zabara | Systems and methods for therapeutically treating neuro-psychiatric disorders and other illnesses |
US10912712B2 (en) | 2004-03-25 | 2021-02-09 | The Feinstein Institutes For Medical Research | Treatment of bleeding by non-invasive stimulation |
JP2007530586A (en) * | 2004-03-25 | 2007-11-01 | ザ ファインスタイン インスティテュート フォー メディカル リサーチ | Nervous hemostasis |
US7747323B2 (en) | 2004-06-08 | 2010-06-29 | Cardiac Pacemakers, Inc. | Adaptive baroreflex stimulation therapy for disordered breathing |
US7596413B2 (en) * | 2004-06-08 | 2009-09-29 | Cardiac Pacemakers, Inc. | Coordinated therapy for disordered breathing including baroreflex modulation |
WO2006041922A2 (en) * | 2004-10-08 | 2006-04-20 | Dara Biosciences, Inc. | Agents and methods for administration to the central nervous system |
EP2298410B1 (en) | 2004-12-27 | 2013-10-09 | The Feinstein Institute for Medical Research | Treating inflammatory disorders by electrical vagus nerve stimulation |
US11207518B2 (en) | 2004-12-27 | 2021-12-28 | The Feinstein Institutes For Medical Research | Treating inflammatory disorders by stimulation of the cholinergic anti-inflammatory pathway |
US8565867B2 (en) * | 2005-01-28 | 2013-10-22 | Cyberonics, Inc. | Changeable electrode polarity stimulation by an implantable medical device |
US8260426B2 (en) | 2008-01-25 | 2012-09-04 | Cyberonics, Inc. | Method, apparatus and system for bipolar charge utilization during stimulation by an implantable medical device |
US9314633B2 (en) | 2008-01-25 | 2016-04-19 | Cyberonics, Inc. | Contingent cardio-protection for epilepsy patients |
US20070026079A1 (en) * | 2005-02-14 | 2007-02-01 | Louis Herlands | Intranasal administration of modulators of hypothalamic ATP-sensitive potassium channels |
US7711419B2 (en) * | 2005-07-13 | 2010-05-04 | Cyberonics, Inc. | Neurostimulator with reduced size |
US7499752B2 (en) * | 2005-07-29 | 2009-03-03 | Cyberonics, Inc. | Selective nerve stimulation for the treatment of eating disorders |
US20070027499A1 (en) * | 2005-07-29 | 2007-02-01 | Cyberonics, Inc. | Neurostimulation device for treating mood disorders |
US8428731B2 (en) | 2005-10-27 | 2013-04-23 | Cyberonics, Inc. | Sequenced therapy protocols for an implantable medical device |
US7555344B2 (en) * | 2005-10-28 | 2009-06-30 | Cyberonics, Inc. | Selective neurostimulation for treating epilepsy |
US8694118B2 (en) | 2005-10-28 | 2014-04-08 | Cyberonics, Inc. | Variable output ramping for an implantable medical device |
US8725243B2 (en) * | 2005-12-28 | 2014-05-13 | Cyberonics, Inc. | Methods and systems for recommending an appropriate pharmacological treatment to a patient for managing epilepsy and other neurological disorders |
US20070149952A1 (en) * | 2005-12-28 | 2007-06-28 | Mike Bland | Systems and methods for characterizing a patient's propensity for a neurological event and for communicating with a pharmacological agent dispenser |
US8868172B2 (en) * | 2005-12-28 | 2014-10-21 | Cyberonics, Inc. | Methods and systems for recommending an appropriate action to a patient for managing epilepsy and other neurological disorders |
US8109879B2 (en) * | 2006-01-10 | 2012-02-07 | Cardiac Pacemakers, Inc. | Assessing autonomic activity using baroreflex analysis |
US7996079B2 (en) | 2006-01-24 | 2011-08-09 | Cyberonics, Inc. | Input response override for an implantable medical device |
US7657310B2 (en) | 2006-01-26 | 2010-02-02 | Cyberonics, Inc. | Treatment of reproductive endocrine disorders by vagus nerve stimulation |
US7974697B2 (en) * | 2006-01-26 | 2011-07-05 | Cyberonics, Inc. | Medical imaging feedback for an implantable medical device |
US7801601B2 (en) * | 2006-01-27 | 2010-09-21 | Cyberonics, Inc. | Controlling neuromodulation using stimulus modalities |
US20070287931A1 (en) * | 2006-02-14 | 2007-12-13 | Dilorenzo Daniel J | Methods and systems for administering an appropriate pharmacological treatment to a patient for managing epilepsy and other neurological disorders |
ES2573323T3 (en) | 2006-03-29 | 2016-06-07 | Dignity Health | Electrical stimulation of cranial nerve microburst for the treatment of medical conditions |
US7869885B2 (en) * | 2006-04-28 | 2011-01-11 | Cyberonics, Inc | Threshold optimization for tissue stimulation therapy |
US7962220B2 (en) | 2006-04-28 | 2011-06-14 | Cyberonics, Inc. | Compensation reduction in tissue stimulation therapy |
US20080027348A1 (en) * | 2006-06-23 | 2008-01-31 | Neuro Vista Corporation | Minimally Invasive Monitoring Systems for Monitoring a Patient's Propensity for a Neurological Event |
US7869867B2 (en) | 2006-10-27 | 2011-01-11 | Cyberonics, Inc. | Implantable neurostimulator with refractory stimulation |
US8295934B2 (en) * | 2006-11-14 | 2012-10-23 | Neurovista Corporation | Systems and methods of reducing artifact in neurological stimulation systems |
WO2008092133A2 (en) * | 2007-01-25 | 2008-07-31 | Neurovista Corporation | Methods and systems for measuring a subject's susceptibility to a seizure |
US7706875B2 (en) | 2007-01-25 | 2010-04-27 | Cyberonics, Inc. | Modulation of drug effects by vagus nerve stimulation |
US9898656B2 (en) | 2007-01-25 | 2018-02-20 | Cyberonics, Inc. | Systems and methods for identifying a contra-ictal condition in a subject |
US20080208074A1 (en) * | 2007-02-21 | 2008-08-28 | David Snyder | Methods and Systems for Characterizing and Generating a Patient-Specific Seizure Advisory System |
EP2129352B1 (en) * | 2007-03-13 | 2016-03-09 | The Feinstein Institute for Medical Research | Treatment of inflammation by non-invasive stimulation |
US8036736B2 (en) | 2007-03-21 | 2011-10-11 | Neuro Vista Corporation | Implantable systems and methods for identifying a contra-ictal condition in a subject |
US7962214B2 (en) | 2007-04-26 | 2011-06-14 | Cyberonics, Inc. | Non-surgical device and methods for trans-esophageal vagus nerve stimulation |
US7869884B2 (en) * | 2007-04-26 | 2011-01-11 | Cyberonics, Inc. | Non-surgical device and methods for trans-esophageal vagus nerve stimulation |
US7904175B2 (en) | 2007-04-26 | 2011-03-08 | Cyberonics, Inc. | Trans-esophageal vagus nerve stimulation |
US7974701B2 (en) * | 2007-04-27 | 2011-07-05 | Cyberonics, Inc. | Dosing limitation for an implantable medical device |
US9788744B2 (en) | 2007-07-27 | 2017-10-17 | Cyberonics, Inc. | Systems for monitoring brain activity and patient advisory device |
US8391970B2 (en) | 2007-08-27 | 2013-03-05 | The Feinstein Institute For Medical Research | Devices and methods for inhibiting granulocyte activation by neural stimulation |
WO2009065101A1 (en) * | 2007-11-16 | 2009-05-22 | Mclean Hospital Corporation | Intracranial electrical seizure therapy (icest) |
US9259591B2 (en) * | 2007-12-28 | 2016-02-16 | Cyberonics, Inc. | Housing for an implantable medical device |
US20090171168A1 (en) * | 2007-12-28 | 2009-07-02 | Leyde Kent W | Systems and Method for Recording Clinical Manifestations of a Seizure |
US8337404B2 (en) | 2010-10-01 | 2012-12-25 | Flint Hills Scientific, Llc | Detecting, quantifying, and/or classifying seizures using multimodal data |
US8382667B2 (en) | 2010-10-01 | 2013-02-26 | Flint Hills Scientific, Llc | Detecting, quantifying, and/or classifying seizures using multimodal data |
US8571643B2 (en) | 2010-09-16 | 2013-10-29 | Flint Hills Scientific, Llc | Detecting or validating a detection of a state change from a template of heart rate derivative shape or heart beat wave complex |
US9579506B2 (en) | 2008-01-25 | 2017-02-28 | Flint Hills Scientific, L.L.C. | Contingent cardio-protection for epilepsy patients |
WO2009146030A1 (en) * | 2008-03-31 | 2009-12-03 | The Feinstein Institute For Medical Research | Methods and systems for reducing inflammation by neuromodulation of t-cell activity |
US9662490B2 (en) | 2008-03-31 | 2017-05-30 | The Feinstein Institute For Medical Research | Methods and systems for reducing inflammation by neuromodulation and administration of an anti-inflammatory drug |
US8204603B2 (en) | 2008-04-25 | 2012-06-19 | Cyberonics, Inc. | Blocking exogenous action potentials by an implantable medical device |
US20090275997A1 (en) * | 2008-05-01 | 2009-11-05 | Michael Allen Faltys | Vagus nerve stimulation electrodes and methods of use |
US8473062B2 (en) * | 2008-05-01 | 2013-06-25 | Autonomic Technologies, Inc. | Method and device for the treatment of headache |
US8457747B2 (en) | 2008-10-20 | 2013-06-04 | Cyberonics, Inc. | Neurostimulation with signal duration determined by a cardiac cycle |
US8417344B2 (en) | 2008-10-24 | 2013-04-09 | Cyberonics, Inc. | Dynamic cranial nerve stimulation based on brain state determination from cardiac data |
EP2355893B1 (en) * | 2008-11-18 | 2013-12-25 | Setpoint Medical Corporation | Devices for optimizing electrode placement for anti-inflamatory stimulation |
EP2369986A4 (en) * | 2008-12-23 | 2013-08-28 | Neurovista Corp | Brain state analysis based on select seizure onset characteristics and clinical manifestations |
US8849390B2 (en) | 2008-12-29 | 2014-09-30 | Cyberonics, Inc. | Processing for multi-channel signals |
US8412336B2 (en) | 2008-12-29 | 2013-04-02 | Autonomic Technologies, Inc. | Integrated delivery and visualization tool for a neuromodulation system |
US8588933B2 (en) | 2009-01-09 | 2013-11-19 | Cyberonics, Inc. | Medical lead termination sleeve for implantable medical devices |
US8494641B2 (en) | 2009-04-22 | 2013-07-23 | Autonomic Technologies, Inc. | Implantable neurostimulator with integral hermetic electronic enclosure, circuit substrate, monolithic feed-through, lead assembly and anchoring mechanism |
US9320908B2 (en) * | 2009-01-15 | 2016-04-26 | Autonomic Technologies, Inc. | Approval per use implanted neurostimulator |
US20100185249A1 (en) * | 2009-01-22 | 2010-07-22 | Wingeier Brett M | Method and Devices for Adrenal Stimulation |
US20100191304A1 (en) | 2009-01-23 | 2010-07-29 | Scott Timothy L | Implantable Medical Device for Providing Chronic Condition Therapy and Acute Condition Therapy Using Vagus Nerve Stimulation |
US8827912B2 (en) | 2009-04-24 | 2014-09-09 | Cyberonics, Inc. | Methods and systems for detecting epileptic events using NNXX, optionally with nonlinear analysis parameters |
US8239028B2 (en) * | 2009-04-24 | 2012-08-07 | Cyberonics, Inc. | Use of cardiac parameters in methods and systems for treating a chronic medical condition |
US9211410B2 (en) | 2009-05-01 | 2015-12-15 | Setpoint Medical Corporation | Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation |
US8996116B2 (en) | 2009-10-30 | 2015-03-31 | Setpoint Medical Corporation | Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction |
US8786624B2 (en) | 2009-06-02 | 2014-07-22 | Cyberonics, Inc. | Processing for multi-channel signals |
AU2010258792B2 (en) | 2009-06-09 | 2015-07-02 | Setpoint Medical Corporation | Nerve cuff with pocket for leadless stimulator |
US9833621B2 (en) | 2011-09-23 | 2017-12-05 | Setpoint Medical Corporation | Modulation of sirtuins by vagus nerve stimulation |
US11051744B2 (en) | 2009-11-17 | 2021-07-06 | Setpoint Medical Corporation | Closed-loop vagus nerve stimulation |
AU2010336337B2 (en) | 2009-12-23 | 2016-02-04 | Setpoint Medical Corporation | Neural stimulation devices and systems for treatment of chronic inflammation |
US9643019B2 (en) | 2010-02-12 | 2017-05-09 | Cyberonics, Inc. | Neurological monitoring and alerts |
US20110218820A1 (en) * | 2010-03-02 | 2011-09-08 | Himes David M | Displaying and Manipulating Brain Function Data Including Filtering of Annotations |
US20110219325A1 (en) * | 2010-03-02 | 2011-09-08 | Himes David M | Displaying and Manipulating Brain Function Data Including Enhanced Data Scrolling Functionality |
US8649871B2 (en) | 2010-04-29 | 2014-02-11 | Cyberonics, Inc. | Validity test adaptive constraint modification for cardiac data used for detection of state changes |
US8562536B2 (en) | 2010-04-29 | 2013-10-22 | Flint Hills Scientific, Llc | Algorithm for detecting a seizure from cardiac data |
US8831732B2 (en) | 2010-04-29 | 2014-09-09 | Cyberonics, Inc. | Method, apparatus and system for validating and quantifying cardiac beat data quality |
US8594806B2 (en) | 2010-04-30 | 2013-11-26 | Cyberonics, Inc. | Recharging and communication lead for an implantable device |
US8788045B2 (en) | 2010-06-08 | 2014-07-22 | Bluewind Medical Ltd. | Tibial nerve stimulation |
US8679009B2 (en) | 2010-06-15 | 2014-03-25 | Flint Hills Scientific, Llc | Systems approach to comorbidity assessment |
US8641646B2 (en) | 2010-07-30 | 2014-02-04 | Cyberonics, Inc. | Seizure detection using coordinate data |
US8684921B2 (en) | 2010-10-01 | 2014-04-01 | Flint Hills Scientific Llc | Detecting, assessing and managing epilepsy using a multi-variate, metric-based classification analysis |
US9186504B2 (en) | 2010-11-15 | 2015-11-17 | Rainbow Medical Ltd | Sleep apnea treatment |
US9457186B2 (en) | 2010-11-15 | 2016-10-04 | Bluewind Medical Ltd. | Bilateral feedback |
US9504390B2 (en) | 2011-03-04 | 2016-11-29 | Globalfoundries Inc. | Detecting, assessing and managing a risk of death in epilepsy |
US8725239B2 (en) | 2011-04-25 | 2014-05-13 | Cyberonics, Inc. | Identifying seizures using heart rate decrease |
US9402550B2 (en) | 2011-04-29 | 2016-08-02 | Cybertronics, Inc. | Dynamic heart rate threshold for neurological event detection |
WO2012154865A2 (en) | 2011-05-09 | 2012-11-15 | Setpoint Medical Corporation | Single-pulse activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation |
US10206591B2 (en) | 2011-10-14 | 2019-02-19 | Flint Hills Scientific, Llc | Seizure detection methods, apparatus, and systems using an autoregression algorithm |
WO2013112920A1 (en) | 2012-01-25 | 2013-08-01 | Nevro Corporation | Lead anchors and associated systems and methods |
US20150018728A1 (en) | 2012-01-26 | 2015-01-15 | Bluewind Medical Ltd. | Wireless neurostimulators |
US9572983B2 (en) | 2012-03-26 | 2017-02-21 | Setpoint Medical Corporation | Devices and methods for modulation of bone erosion |
US10448839B2 (en) | 2012-04-23 | 2019-10-22 | Livanova Usa, Inc. | Methods, systems and apparatuses for detecting increased risk of sudden death |
US9343923B2 (en) | 2012-08-23 | 2016-05-17 | Cyberonics, Inc. | Implantable medical device with backscatter signal based communication |
US9935498B2 (en) | 2012-09-25 | 2018-04-03 | Cyberonics, Inc. | Communication efficiency with an implantable medical device using a circulator and a backscatter signal |
WO2014087337A1 (en) | 2012-12-06 | 2014-06-12 | Bluewind Medical Ltd. | Delivery of implantable neurostimulators |
US9435830B2 (en) | 2013-01-18 | 2016-09-06 | Cyberonics, Inc. | Implantable medical device depth estimation |
US10220211B2 (en) | 2013-01-22 | 2019-03-05 | Livanova Usa, Inc. | Methods and systems to diagnose depression |
US9056195B2 (en) | 2013-03-15 | 2015-06-16 | Cyberonics, Inc. | Optimization of cranial nerve stimulation to treat seizure disorderse during sleep |
US9265935B2 (en) | 2013-06-28 | 2016-02-23 | Nevro Corporation | Neurological stimulation lead anchors and associated systems and methods |
US9585611B2 (en) | 2014-04-25 | 2017-03-07 | Cyberonics, Inc. | Detecting seizures based on heartbeat data |
US9302109B2 (en) | 2014-04-25 | 2016-04-05 | Cyberonics, Inc. | Cranial nerve stimulation to treat depression during sleep |
US11311725B2 (en) | 2014-10-24 | 2022-04-26 | Setpoint Medical Corporation | Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation |
US9597521B2 (en) | 2015-01-21 | 2017-03-21 | Bluewind Medical Ltd. | Transmitting coils for neurostimulation |
US9764146B2 (en) | 2015-01-21 | 2017-09-19 | Bluewind Medical Ltd. | Extracorporeal implant controllers |
US10004896B2 (en) | 2015-01-21 | 2018-06-26 | Bluewind Medical Ltd. | Anchors and implant devices |
US11406833B2 (en) | 2015-02-03 | 2022-08-09 | Setpoint Medical Corporation | Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator |
US9782589B2 (en) | 2015-06-10 | 2017-10-10 | Bluewind Medical Ltd. | Implantable electrostimulator for improving blood flow |
US9713707B2 (en) | 2015-11-12 | 2017-07-25 | Bluewind Medical Ltd. | Inhibition of implant migration |
US10596367B2 (en) | 2016-01-13 | 2020-03-24 | Setpoint Medical Corporation | Systems and methods for establishing a nerve block |
WO2017127758A1 (en) | 2016-01-20 | 2017-07-27 | Setpoint Medical Corporation | Implantable microstimulators and inductive charging systems |
CN108882885A (en) | 2016-01-20 | 2018-11-23 | 赛博恩特医疗器械公司 | The control of vagal stimulation |
US11471681B2 (en) | 2016-01-20 | 2022-10-18 | Setpoint Medical Corporation | Batteryless implantable microstimulators |
US10583304B2 (en) | 2016-01-25 | 2020-03-10 | Setpoint Medical Corporation | Implantable neurostimulator having power control and thermal regulation and methods of use |
US11213687B2 (en) | 2016-02-03 | 2022-01-04 | The Charles Stark Draper Laboratory, Inc. | Neural implant for microstimulation |
US10039923B2 (en) | 2016-02-03 | 2018-08-07 | The Charles Stark Draper Laboratory, Inc. | Neural implant for microstimulation |
US10124178B2 (en) | 2016-11-23 | 2018-11-13 | Bluewind Medical Ltd. | Implant and delivery tool therefor |
US20180353764A1 (en) | 2017-06-13 | 2018-12-13 | Bluewind Medical Ltd. | Antenna configuration |
US11173307B2 (en) | 2017-08-14 | 2021-11-16 | Setpoint Medical Corporation | Vagus nerve stimulation pre-screening test |
US11260229B2 (en) | 2018-09-25 | 2022-03-01 | The Feinstein Institutes For Medical Research | Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation |
US11938324B2 (en) | 2020-05-21 | 2024-03-26 | The Feinstein Institutes For Medical Research | Systems and methods for vagus nerve stimulation |
US11400299B1 (en) | 2021-09-14 | 2022-08-02 | Rainbow Medical Ltd. | Flexible antenna for stimulator |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2533360A1 (en) * | 1975-07-25 | 1977-02-17 | Cooper Irving S | Brain stimulating electrical impulse apparatus - has two sets of electrodes applied to cerebellum with alternating pulse bursts |
US5441528A (en) * | 1992-09-25 | 1995-08-15 | Symtonic, S.A. | Method and system for applying low energy emission therapy |
-
2000
- 2000-11-30 US US09/727,570 patent/US6356788B2/en not_active Expired - Fee Related
Cited By (225)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020062060A1 (en) * | 1998-10-06 | 2002-05-23 | Yossi Gross | Incontinence treatment device |
US7387603B2 (en) | 1998-10-06 | 2008-06-17 | Ams Research Corporation | Incontinence treatment device |
US20050113881A1 (en) * | 1998-10-06 | 2005-05-26 | Yossi Gross | Incontinence treatment device |
US6896651B2 (en) | 1998-10-06 | 2005-05-24 | Biocontrol Medical Ltd. | Mechanical and electrical sensing for incontinence treatment |
US7865243B1 (en) | 2000-04-07 | 2011-01-04 | Boston Scientific Neuromodulation Corporation | Device and therapy for erectile dysfunction and other sexual dysfunction |
US7890177B1 (en) | 2000-04-07 | 2011-02-15 | Boston Scientific Neuromodulation Corporation | Device and therapy for erectile dysfunction and other sexual dysfunction |
US8412334B2 (en) | 2000-06-20 | 2013-04-02 | Boston Scientific Neuromodulation Corporation | Treatment of mood and/or anxiety disorders by electrical brain stimulation and/or drug infusion |
US8718779B2 (en) | 2000-06-20 | 2014-05-06 | Boston Scientific Neuromodulation Corporation | Treatment of mood and/or anxiety disorders by electrical brain stimulation and/or drug infusion |
US8046076B2 (en) * | 2000-06-20 | 2011-10-25 | Boston Scientific Neuromodulation Corporation | Treatment of mood and/or anxiety disorders by electrical brain stimulation and/or drug infusion |
US20050049651A1 (en) * | 2000-06-20 | 2005-03-03 | Whitehurst Todd K. | Treatment of mood and/or anxiety disorders by electrical brain stimulation and/or drug infusion |
US8086314B1 (en) | 2000-09-27 | 2011-12-27 | Cvrx, Inc. | Devices and methods for cardiovascular reflex control |
US8606359B2 (en) | 2000-09-27 | 2013-12-10 | Cvrx, Inc. | System and method for sustained baroreflex stimulation |
US20070038255A1 (en) * | 2000-09-27 | 2007-02-15 | Cvrx, Inc. | Baroreflex stimulator with integrated pressure sensor |
US8838246B2 (en) | 2000-09-27 | 2014-09-16 | Cvrx, Inc. | Devices and methods for cardiovascular reflex treatments |
US8290595B2 (en) | 2000-09-27 | 2012-10-16 | Cvrx, Inc. | Method and apparatus for stimulation of baroreceptors in pulmonary artery |
US8718789B2 (en) | 2000-09-27 | 2014-05-06 | Cvrx, Inc. | Electrode structures and methods for their use in cardiovascular reflex control |
US8583236B2 (en) | 2000-09-27 | 2013-11-12 | Cvrx, Inc. | Devices and methods for cardiovascular reflex control |
US9427583B2 (en) | 2000-09-27 | 2016-08-30 | Cvrx, Inc. | Electrode structures and methods for their use in cardiovascular reflex control |
US20070021790A1 (en) * | 2000-09-27 | 2007-01-25 | Cvrx, Inc. | Automatic baroreflex modulation responsive to adverse event |
US8060206B2 (en) | 2000-09-27 | 2011-11-15 | Cvrx, Inc. | Baroreflex modulation to gradually decrease blood pressure |
US20080177350A1 (en) * | 2000-09-27 | 2008-07-24 | Cvrx, Inc. | Expandable Stimulation Electrode with Integrated Pressure Sensor and Methods Related Thereto |
US7813812B2 (en) | 2000-09-27 | 2010-10-12 | Cvrx, Inc. | Baroreflex stimulator with integrated pressure sensor |
US20050251212A1 (en) * | 2000-09-27 | 2005-11-10 | Cvrx, Inc. | Stimulus regimens for cardiovascular reflex control |
US9044609B2 (en) | 2000-09-27 | 2015-06-02 | Cvrx, Inc. | Electrode structures and methods for their use in cardiovascular reflex control |
US7949400B2 (en) | 2000-09-27 | 2011-05-24 | Cvrx, Inc. | Devices and methods for cardiovascular reflex control via coupled electrodes |
US8880190B2 (en) | 2000-09-27 | 2014-11-04 | Cvrx, Inc. | Electrode structures and methods for their use in cardiovascular reflex control |
US8712531B2 (en) | 2000-09-27 | 2014-04-29 | Cvrx, Inc. | Automatic baroreflex modulation responsive to adverse event |
US7840271B2 (en) | 2000-09-27 | 2010-11-23 | Cvrx, Inc. | Stimulus regimens for cardiovascular reflex control |
US7616998B2 (en) | 2000-10-30 | 2009-11-10 | Medtronic, Inc. | Electrical stimulation of structures within the brain |
US6871098B2 (en) | 2000-10-30 | 2005-03-22 | Medtronic, Inc. | Method for treating obsessive-compulsive disorder with electrical stimulation of the brain internal capsule |
US20050049650A1 (en) * | 2000-10-30 | 2005-03-03 | Medtronic, Inc. | Method for treating obsessive-compulsive disorder with electrical stimulation of the brain internal capsule |
US20050240229A1 (en) * | 2001-04-26 | 2005-10-27 | Whitehurst Tood K | Methods and systems for stimulation as a therapy for erectile dysfunction |
US7660631B2 (en) | 2001-04-26 | 2010-02-09 | Boston Scientific Neuromodulation Corporation | Methods and systems for electrical and/or drug stimulation as a therapy for erectile dysfunction |
US20050209652A1 (en) * | 2001-04-26 | 2005-09-22 | Whitehurst Todd K | Methods and systems for electrical and/or drug stimulation as a therapy for erectile dysfunction |
US7734355B2 (en) | 2001-08-31 | 2010-06-08 | Bio Control Medical (B.C.M.) Ltd. | Treatment of disorders by unidirectional nerve stimulation |
US8571653B2 (en) | 2001-08-31 | 2013-10-29 | Bio Control Medical (B.C.M.) Ltd. | Nerve stimulation techniques |
US20090228065A1 (en) * | 2001-09-26 | 2009-09-10 | Cvrx, Inc. | Implantable vascular structures and methods for their use |
US20030082884A1 (en) * | 2001-10-26 | 2003-05-01 | International Business Machine Corporation And Kabushiki Kaisha Toshiba | Method of forming low-leakage dielectric layer |
US7308303B2 (en) | 2001-11-01 | 2007-12-11 | Advanced Bionics Corporation | Thrombolysis and chronic anticoagulation therapy |
US20030083698A1 (en) * | 2001-11-01 | 2003-05-01 | Whitehurst Todd K. | Thrombolysis and chronic anticoagulation therapy |
US20030171789A1 (en) * | 2001-11-01 | 2003-09-11 | Medtronic, Inc. | Method and apparatus for programming an implantable medical device |
US7187978B2 (en) | 2001-11-01 | 2007-03-06 | Medtronic, Inc. | Method and apparatus for programming an implantable medical device |
US20080286327A1 (en) * | 2001-11-01 | 2008-11-20 | Whitehurst Todd K | Thombolysis and chronic anticoagulation therapy |
WO2003037430A3 (en) * | 2001-11-01 | 2003-12-18 | Medtronic Inc | Method and apparatus for programming an implantable medical device |
US7877137B2 (en) | 2001-11-01 | 2011-01-25 | Boston Scientific Neuromodulation Corporation | Thrombolysis and chronic anticoagulation therapy |
US8280502B2 (en) | 2002-02-04 | 2012-10-02 | Cerephex Corporation | Method and apparatus for utilizing amplitude-modulated pulse-width modulation signals for neurostimulation and treatment of neurological disorders using electrical stimulation |
US20100204750A1 (en) * | 2002-02-04 | 2010-08-12 | Cerephex Corporation | Method and apparatus for utilizing amplitude-modulated pulse-width modulation signals for neurostimulation and treatment of neurological disorders using electrical stimulation |
US7715910B2 (en) | 2002-02-04 | 2010-05-11 | Cerephex Corporation | Method and apparatus for utilizing amplitude-modulated pulse-width modulation signals for neurostimulation and treatment of neurological disorders using electrical stimulation |
US20060258950A1 (en) * | 2002-02-04 | 2006-11-16 | Synergistic Neurotherapy Adjustment Process, Inc. (Trade At Synaps) | Method and apparatus for utilizing amplitude-modulated pulse-width modulation signals for neurostimulation and treatment of neurological disorders using electrical stimulation |
US9616234B2 (en) | 2002-05-03 | 2017-04-11 | Trustees Of Boston University | System and method for neuro-stimulation |
US20070100393A1 (en) * | 2002-05-24 | 2007-05-03 | Whitehurst Todd K | Treatment of movement disorders by brain stimulation |
US20100331807A1 (en) * | 2002-05-24 | 2010-12-30 | Boston Scientific Neuromodulation Corporation | Treatment of movement disorders by brain stimulation |
US7151961B1 (en) * | 2002-05-24 | 2006-12-19 | Advanced Bionics Corporation | Treatment of movement disorders by brain stimulation |
US8401634B2 (en) | 2002-05-24 | 2013-03-19 | Boston Scientific Neuromodulation Corporation | Treatment of movement disorders by brain stimulation |
US20030236557A1 (en) * | 2002-06-20 | 2003-12-25 | Whitehurst Todd K. | Cavernous nerve stimulation via unidirectional propagation of action potentials |
US9409028B2 (en) | 2002-06-20 | 2016-08-09 | Boston Scientific Neuromodulation Corporation | Implantable microstimulators with programmable multielectrode configuration and uses thereof |
US8548604B2 (en) | 2002-06-20 | 2013-10-01 | Boston Scientific Neuromodulation Corporation | Implantable microstimulators and methods for unidirectional propagation of action potentials |
US7860570B2 (en) | 2002-06-20 | 2010-12-28 | Boston Scientific Neuromodulation Corporation | Implantable microstimulators and methods for unidirectional propagation of action potentials |
US7203548B2 (en) | 2002-06-20 | 2007-04-10 | Advanced Bionics Corporation | Cavernous nerve stimulation via unidirectional propagation of action potentials |
US7292890B2 (en) * | 2002-06-20 | 2007-11-06 | Advanced Bionics Corporation | Vagus nerve stimulation via unidirectional propagation of action potentials |
US20070021800A1 (en) * | 2002-06-20 | 2007-01-25 | Advanced Bionics Corporation, A California Corporation | Cavernous nerve stimulation via unidirectional propagation of action potentials |
US9283394B2 (en) | 2002-06-20 | 2016-03-15 | Boston Scientific Neuromodulation Corporation | Implantable microstimulators and methods for unidirectional propagation of action potentials |
US7899539B2 (en) | 2002-06-20 | 2011-03-01 | Boston Scientific Neuromodulation Corporation | Cavernous nerve stimulation via unidirectional propagation of action potentials |
US20030236558A1 (en) * | 2002-06-20 | 2003-12-25 | Whitehurst Todd K. | Vagus nerve stimulation via unidirectional propagation of action potentials |
US20040015205A1 (en) * | 2002-06-20 | 2004-01-22 | Whitehurst Todd K. | Implantable microstimulators with programmable multielectrode configuration and uses thereof |
US7783362B2 (en) | 2002-06-20 | 2010-08-24 | Boston Scientific Neuromodulation Corporation | Vagus nerve stimulation via unidirectional propagation of action potentials |
US20040015204A1 (en) * | 2002-06-20 | 2004-01-22 | Whitehurst Todd K. | Implantable microstimulators and methods for unidirectional propagation of action potentials |
US8712547B2 (en) | 2002-06-20 | 2014-04-29 | Boston Scientific Neuromodulation Corporation | Cavernous nerve stimulation via unidirectional propagation of action potentials |
US20050182287A1 (en) * | 2002-10-21 | 2005-08-18 | Becker Paul F. | Method and apparatus for the treatment of physical and mental disorders with low frequency, low flux density magnetic fields |
US6899667B2 (en) * | 2002-10-21 | 2005-05-31 | Paul F. Becker | Method and apparatus for the treatment of physical and mental disorders with low frequency, low flux density magnetic fields |
US20100298624A1 (en) * | 2002-10-21 | 2010-11-25 | Becker Paul F | Method and apparatus for the treatment of physical and mental disorders with low frequency, low flux density magnetic fields |
US7988613B2 (en) | 2002-10-21 | 2011-08-02 | Becker Paul F | Method and apparatus for the treatment of physical and mental disorders with low frequency, low flux density magnetic fields |
US7276020B2 (en) | 2002-10-21 | 2007-10-02 | Becker Paul F | Method and apparatus for the treatment of physical and mental disorders with low frequency, low flux density magnetic fields |
US7819794B2 (en) | 2002-10-21 | 2010-10-26 | Becker Paul F | Method and apparatus for the treatment of physical and mental disorders with low frequency, low flux density magnetic fields |
US20050027158A1 (en) * | 2002-10-21 | 2005-02-03 | Becker Paul F. | Method and apparatus for the treatment of physical and mental disorders with low frequency, low flux density magnetic fields |
US20060111626A1 (en) * | 2003-03-27 | 2006-05-25 | Cvrx, Inc. | Electrode structures having anti-inflammatory properties and methods of use |
US20040243205A1 (en) * | 2003-05-30 | 2004-12-02 | Medtronic, Inc. | Implantable cortical neural lead and method |
US7107104B2 (en) | 2003-05-30 | 2006-09-12 | Medtronic, Inc. | Implantable cortical neural lead and method |
WO2005039693A1 (en) * | 2003-10-27 | 2005-05-06 | Jorge Alberto Morales Sanchez | Device for emitting electric impulses directed to the brain |
US20100268288A1 (en) * | 2003-11-20 | 2010-10-21 | Angiotech International Ag | Electrical devices and anti-scarring agents |
US20050182467A1 (en) * | 2003-11-20 | 2005-08-18 | Angiotech International Ag | Electrical devices and anti-scarring agents |
US20060161219A1 (en) * | 2003-11-20 | 2006-07-20 | Advanced Neuromodulation Systems, Inc. | Electrical stimulation system and method for stimulating multiple locations of target nerve tissue in the brain to treat multiple conditions in the body |
US7751891B2 (en) * | 2004-07-28 | 2010-07-06 | Cyberonics, Inc. | Power supply monitoring for an implantable device |
US20060025829A1 (en) * | 2004-07-28 | 2006-02-02 | Armstrong Randolph K | Power supply monitoring for an implantable device |
US7502651B2 (en) | 2004-09-08 | 2009-03-10 | Spinal Modulation, Inc. | Methods for stimulating a dorsal root ganglion |
US20060052838A1 (en) * | 2004-09-08 | 2006-03-09 | Kim Daniel H | Methods of neurostimulating targeted neural tissue |
US8712546B2 (en) | 2004-09-08 | 2014-04-29 | Spinal Modulation, Inc. | Neurostimulation system |
US9205259B2 (en) | 2004-09-08 | 2015-12-08 | The Board Of Trustees Of The Leland Stanford Junior University | Neurostimulation system |
US9205261B2 (en) | 2004-09-08 | 2015-12-08 | The Board Of Trustees Of The Leland Stanford Junior University | Neurostimulation methods and systems |
US20080167698A1 (en) * | 2004-09-08 | 2008-07-10 | Spinal Modulation, Inc. | Neurostimulation system |
US9205260B2 (en) | 2004-09-08 | 2015-12-08 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for stimulating a dorsal root ganglion |
US7447546B2 (en) | 2004-09-08 | 2008-11-04 | Spinal Modulation, Inc. | Methods of neurostimulating targeted neural tissue |
US20060052827A1 (en) * | 2004-09-08 | 2006-03-09 | Kim Daniel H | Stimulation systems |
US7450993B2 (en) | 2004-09-08 | 2008-11-11 | Spinal Modulation, Inc. | Methods for selective stimulation of a ganglion |
US8229565B2 (en) | 2004-09-08 | 2012-07-24 | Spinal Modulation, Inc. | Methods for stimulating a dorsal root ganglion |
US9486633B2 (en) | 2004-09-08 | 2016-11-08 | The Board Of Trustees Of The Leland Stanford Junior University | Selective stimulation to modulate the sympathetic nervous system |
US20060052856A1 (en) * | 2004-09-08 | 2006-03-09 | Kim Daniel H | Stimulation components |
US20060052826A1 (en) * | 2004-09-08 | 2006-03-09 | Kim Daniel H | Pulse generator for high impedance electrodes |
US10159838B2 (en) | 2004-09-08 | 2018-12-25 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for stimulating a dorsal root ganglion |
US10232180B2 (en) | 2004-09-08 | 2019-03-19 | The Board Of Trustees Of The Leland Stanford Junior University | Selective stimulation to modulate the sympathetic nervous system |
US20060052835A1 (en) * | 2004-09-08 | 2006-03-09 | Kim Daniel H | Methods for stimulating the spinal cord and nervous system |
US8082039B2 (en) | 2004-09-08 | 2011-12-20 | Spinal Modulation, Inc. | Stimulation systems |
US20060052839A1 (en) * | 2004-09-08 | 2006-03-09 | Kim Daniel H | Methods for stimulating a dorsal root ganglion |
US20060052836A1 (en) * | 2004-09-08 | 2006-03-09 | Kim Daniel H | Neurostimulation system |
US20090210041A1 (en) * | 2004-09-08 | 2009-08-20 | Kim Daniel H | Methods for stimulating a dorsal root ganglion |
US7580753B2 (en) | 2004-09-08 | 2009-08-25 | Spinal Modulation, Inc. | Method and system for stimulating a dorsal root ganglion |
US20090234420A1 (en) * | 2005-03-11 | 2009-09-17 | Medtronic, Inc. | Implantable neurostimulator device |
US20060206163A1 (en) * | 2005-03-11 | 2006-09-14 | Wahlstrand Carl D | Neurostimulation site screening |
US8744582B2 (en) | 2005-03-11 | 2014-06-03 | Medtronic, Inc. | Implantable neurostimulator device with bellows-like element coupling first and second housing portions |
US8295936B2 (en) | 2005-03-11 | 2012-10-23 | Medtronic, Inc. | Implantable neurostimulator device |
US20100049277A1 (en) * | 2005-03-11 | 2010-02-25 | Medtronic, Inc. | Implantable neurostimulator device |
US20060206162A1 (en) * | 2005-03-11 | 2006-09-14 | Wahlstrand Carl D | Implantable neurostimulator device |
US7555345B2 (en) | 2005-03-11 | 2009-06-30 | Medtronic, Inc. | Implantable neurostimulator device |
US7676271B2 (en) | 2005-03-11 | 2010-03-09 | Medtronic, Inc. | Neurostimulation site screening |
US8620437B2 (en) | 2005-03-11 | 2013-12-31 | Medtronic, Inc. | Method for delivery of electrical stimulation with bendable housing |
US9149628B2 (en) | 2005-03-11 | 2015-10-06 | Medtronic, Inc. | Neurostimulator for treating occipital neuralgia with housing sized and curved to conform to a subcutaneous neck region |
US7231256B2 (en) | 2005-03-11 | 2007-06-12 | Medtronic, Inc. | Neurostimulation site screening |
US20070162087A1 (en) * | 2005-03-11 | 2007-07-12 | Medtronic, Inc. | Neurostimulation site screening |
US20070208391A1 (en) * | 2005-03-11 | 2007-09-06 | Medtronic, Inc. | Neurostimulation site screening |
US7664552B2 (en) | 2005-03-11 | 2010-02-16 | Medtronic, Inc. | Neurostimulation site screening |
US7627383B2 (en) | 2005-03-15 | 2009-12-01 | Boston Scientific Neuromodulation Corporation | Implantable stimulator |
US20110077579A1 (en) * | 2005-03-24 | 2011-03-31 | Harrison William V | Cochlear implant with localized fluid transport |
US7801602B2 (en) | 2005-04-08 | 2010-09-21 | Boston Scientific Neuromodulation Corporation | Controlling stimulation parameters of implanted tissue stimulators |
US20060229688A1 (en) * | 2005-04-08 | 2006-10-12 | Mcclure Kelly H | Controlling stimulation parameters of implanted tissue stimulators |
US9504836B2 (en) | 2005-05-10 | 2016-11-29 | Cardiac Pacemakers, Inc. | System and method to deliver therapy in presence of another therapy |
US8805494B2 (en) | 2005-05-10 | 2014-08-12 | Cardiac Pacemakers, Inc. | System and method to deliver therapy in presence of another therapy |
US9393421B2 (en) | 2005-05-26 | 2016-07-19 | Boston Scientific Neuromodulation Corporation | Controlling charge flow in the electrical stimulation of tissue |
US20100280575A1 (en) * | 2005-05-26 | 2010-11-04 | Boston Scientific Neuromodulation Corporation | Controlling charge flow in the electrical stimulation of tissue |
US11179568B2 (en) | 2005-05-26 | 2021-11-23 | Boston Scientific Neuromodufation Corporation | Controlling charge flow in the electrical stimulation of tissue |
US7801600B1 (en) | 2005-05-26 | 2010-09-21 | Boston Scientific Neuromodulation Corporation | Controlling charge flow in the electrical stimulation of tissue |
US10065039B2 (en) | 2005-05-26 | 2018-09-04 | Boston Scientific Neuromodulation Corporation | Controlling charge flow in the electrical stimulation of tissue |
US20060280655A1 (en) * | 2005-06-08 | 2006-12-14 | California Institute Of Technology | Intravascular diagnostic and therapeutic sampling device |
US20110125136A1 (en) * | 2005-06-08 | 2011-05-26 | Morteza Gharib | Intravascular diagnostic and therapeutic sampling device |
US20070027504A1 (en) * | 2005-07-27 | 2007-02-01 | Cyberonics, Inc. | Cranial nerve stimulation to treat a hearing disorder |
US20070118183A1 (en) * | 2005-11-18 | 2007-05-24 | Mark Gelfand | System and method to modulate phrenic nerve to prevent sleep apnea |
US8244359B2 (en) * | 2005-11-18 | 2012-08-14 | Respicardia, Inc. | System and method to modulate phrenic nerve to prevent sleep apnea |
US10518090B2 (en) | 2005-11-18 | 2019-12-31 | Respicardia, Inc. | System and method to modulate phrenic nerve to prevent sleep apnea |
US11305119B2 (en) | 2005-11-18 | 2022-04-19 | Zoll Respicardia, Inc. | System and method to modulate phrenic nerve to prevent sleep apnea |
US20070123938A1 (en) * | 2005-11-30 | 2007-05-31 | Haller Matthew I | Magnetically coupled microstimulators |
US7729758B2 (en) | 2005-11-30 | 2010-06-01 | Boston Scientific Neuromodulation Corporation | Magnetically coupled microstimulators |
US7570999B2 (en) | 2005-12-20 | 2009-08-04 | Cardiac Pacemakers, Inc. | Implantable device for treating epilepsy and cardiac rhythm disorders |
US9889298B2 (en) | 2006-03-03 | 2018-02-13 | Astora Women's Health, Llc | Electrode sling for treating stress and urge incontinence |
US8195296B2 (en) | 2006-03-03 | 2012-06-05 | Ams Research Corporation | Apparatus for treating stress and urge incontinence |
US20090043356A1 (en) * | 2006-03-03 | 2009-02-12 | Ams Research Corporation | Electrode Sling for Treating Stress and Urge Incontinence |
US20070260288A1 (en) * | 2006-03-03 | 2007-11-08 | Yossi Gross | Apparatus for treating stress and urge incontinence |
US8298176B2 (en) | 2006-06-09 | 2012-10-30 | Neurosystec Corporation | Flow-induced delivery from a drug mass |
US20110071493A1 (en) * | 2006-06-09 | 2011-03-24 | Neurosystec Corporation | Flow-Induced Delivery from a Drug Mass |
US7803148B2 (en) | 2006-06-09 | 2010-09-28 | Neurosystec Corporation | Flow-induced delivery from a drug mass |
US8160710B2 (en) | 2006-07-10 | 2012-04-17 | Ams Research Corporation | Systems and methods for implanting tissue stimulation electrodes in the pelvic region |
US20080015642A1 (en) * | 2006-07-17 | 2008-01-17 | Sherwood Services Ag | Method for stimulation of the vagus nerve |
US8571651B2 (en) | 2006-09-07 | 2013-10-29 | Bio Control Medical (B.C.M.) Ltd. | Techniques for reducing pain associated with nerve stimulation |
US20080097142A1 (en) * | 2006-10-20 | 2008-04-24 | Paul Savage | Magnetic field generator, method of generating a pulsed sinusoidal magnetic wave and magnetic field generator system |
US10406366B2 (en) | 2006-11-17 | 2019-09-10 | Respicardia, Inc. | Transvenous phrenic nerve stimulation system |
US8983624B2 (en) | 2006-12-06 | 2015-03-17 | Spinal Modulation, Inc. | Delivery devices, systems and methods for stimulating nerve tissue on multiple spinal levels |
US9427570B2 (en) | 2006-12-06 | 2016-08-30 | St. Jude Medical Luxembourg Holdings SMI S.A.R.L. (“SJM LUX SMI”) | Expandable stimulation leads and methods of use |
US9314618B2 (en) | 2006-12-06 | 2016-04-19 | Spinal Modulation, Inc. | Implantable flexible circuit leads and methods of use |
US9623233B2 (en) | 2006-12-06 | 2017-04-18 | St. Jude Medical Luxembourg Holdings SMI S.A.R.L. (“SJM LUX SMI”) | Delivery devices, systems and methods for stimulating nerve tissue on multiple spinal levels |
US8518092B2 (en) | 2006-12-06 | 2013-08-27 | Spinal Modulation, Inc. | Hard tissue anchors and delivery devices |
US9744351B1 (en) | 2007-01-22 | 2017-08-29 | Respicardia, Inc. | Device and method for the treatment of breathing disorders and cardiac disorders |
US20080208282A1 (en) * | 2007-01-22 | 2008-08-28 | Mark Gelfand | Device and method for the treatment of breathing disorders and cardiac disorders |
US8909341B2 (en) | 2007-01-22 | 2014-12-09 | Respicardia, Inc. | Device and method for the treatment of breathing disorders and cardiac disorders |
US10300270B2 (en) | 2007-01-22 | 2019-05-28 | Respicardia, Inc. | Device and method for the treatment of breathing disorders and cardiac disorders |
US9044592B2 (en) | 2007-01-29 | 2015-06-02 | Spinal Modulation, Inc. | Sutureless lead retention features |
US11305114B2 (en) | 2007-06-27 | 2022-04-19 | Zoll Respicardia, Inc. | Detecting and treating disordered breathing |
US9987488B1 (en) | 2007-06-27 | 2018-06-05 | Respicardia, Inc. | Detecting and treating disordered breathing |
US8774942B2 (en) | 2007-07-10 | 2014-07-08 | Ams Research Corporation | Tissue anchor |
US9427573B2 (en) | 2007-07-10 | 2016-08-30 | Astora Women's Health, Llc | Deployable electrode lead anchor |
US7877136B1 (en) | 2007-09-28 | 2011-01-25 | Boston Scientific Neuromodulation Corporation | Enhancement of neural signal transmission through damaged neural tissue via hyperpolarizing electrical stimulation current |
US20090112282A1 (en) * | 2007-10-26 | 2009-04-30 | Medtronic, Inc. | Occipital nerve stimulation |
US9427572B2 (en) | 2007-10-26 | 2016-08-30 | Medtronic, Inc. | Implantable medical device with connector blocks |
US9008782B2 (en) | 2007-10-26 | 2015-04-14 | Medtronic, Inc. | Occipital nerve stimulation |
US20090112962A1 (en) * | 2007-10-31 | 2009-04-30 | Research In Motion Limited | Modular squaring in binary field arithmetic |
US11865333B2 (en) | 2008-02-07 | 2024-01-09 | Zoll Respicardia, Inc. | Transvascular medical lead |
US9295846B2 (en) | 2008-02-07 | 2016-03-29 | Respicardia, Inc. | Muscle and nerve stimulation |
US11389648B2 (en) | 2008-02-07 | 2022-07-19 | Zoll Respicardia, Inc. | Transvascular medical lead |
US8433412B1 (en) | 2008-02-07 | 2013-04-30 | Respicardia, Inc. | Muscle and nerve stimulation |
US20100030227A1 (en) * | 2008-07-31 | 2010-02-04 | Medtronic, Inc. | Medical lead implantation |
US9409021B2 (en) | 2008-10-27 | 2016-08-09 | St. Jude Medical Luxembourg Holdings SMI S.A.R.L. | Selective stimulation systems and signal parameters for medical conditions |
US11890472B2 (en) | 2008-10-27 | 2024-02-06 | Tc1 Llc | Selective stimulation systems and signal parameters for medical conditions |
US9056197B2 (en) | 2008-10-27 | 2015-06-16 | Spinal Modulation, Inc. | Selective stimulation systems and signal parameters for medical conditions |
US20100217340A1 (en) * | 2009-02-23 | 2010-08-26 | Ams Research Corporation | Implantable Medical Device Connector System |
US9539433B1 (en) | 2009-03-18 | 2017-01-10 | Astora Women's Health, Llc | Electrode implantation in a pelvic floor muscular structure |
US20120184801A1 (en) * | 2009-03-20 | 2012-07-19 | ElectroCore, LLC | Nerve stimulation methods for averting imminent onset or episode of a disease |
US20120185020A1 (en) * | 2009-03-20 | 2012-07-19 | ElectroCore, LLC. | Nerve stimulation methods for averting imminent onset or episode of a disease |
US10286212B2 (en) * | 2009-03-20 | 2019-05-14 | Electrocore, Inc. | Nerve stimulation methods for averting imminent onset or episode of a disease |
US10252074B2 (en) * | 2009-03-20 | 2019-04-09 | ElectroCore, LLC | Nerve stimulation methods for averting imminent onset or episode of a disease |
US20130245486A1 (en) * | 2009-03-20 | 2013-09-19 | ElectroCore, LLC. | Devices and methods for monitoring non-invasive vagus nerve stimulation |
US9254383B2 (en) * | 2009-03-20 | 2016-02-09 | ElectroCore, LLC | Devices and methods for monitoring non-invasive vagus nerve stimulation |
US10220207B2 (en) * | 2009-03-20 | 2019-03-05 | Electrocore, Inc. | Nerve stimulation methods for averting imminent onset or episode of a disease |
US20160367808A9 (en) * | 2009-03-20 | 2016-12-22 | ElectroCore, LLC | Nerve stimulation methods for averting imminent onset or episode of a disease |
US20130066395A1 (en) * | 2009-03-20 | 2013-03-14 | ElectroCore, LLC. | Nerve stimulation methods for averting imminent onset or episode of a disease |
US9468762B2 (en) | 2009-03-24 | 2016-10-18 | St. Jude Medical Luxembourg Holdings SMI S.A.R.L. (“SJM LUX SMI”) | Pain management with stimulation subthreshold to paresthesia |
US8380318B2 (en) | 2009-03-24 | 2013-02-19 | Spinal Modulation, Inc. | Pain management with stimulation subthreshold to paresthesia |
US9259569B2 (en) | 2009-05-15 | 2016-02-16 | Daniel M. Brounstein | Methods, systems and devices for neuromodulating spinal anatomy |
US9999768B2 (en) | 2009-09-10 | 2018-06-19 | Respicardia, Inc. | Respiratory rectification |
US11883659B2 (en) | 2009-09-10 | 2024-01-30 | Zoll Respicardia, Inc. | Systems for treating disordered breathing by comparing stimulated and unstimulated breathing |
US8233987B2 (en) | 2009-09-10 | 2012-07-31 | Respicardia, Inc. | Respiratory rectification |
US11065443B2 (en) | 2009-09-10 | 2021-07-20 | Zoll Respicardia, Inc. | Respiratory rectification |
US20110060380A1 (en) * | 2009-09-10 | 2011-03-10 | Mark Gelfand | Respiratory rectification |
US9327110B2 (en) | 2009-10-27 | 2016-05-03 | St. Jude Medical Luxembourg Holdings SMI S.A.R.L. (“SJM LUX SMI”) | Devices, systems and methods for the targeted treatment of movement disorders |
US8380312B2 (en) | 2009-12-31 | 2013-02-19 | Ams Research Corporation | Multi-zone stimulation implant system and method |
US11413451B2 (en) | 2010-05-10 | 2022-08-16 | St. Jude Medical Luxembourg Holdings SMI S.A.R.L. (“SJM LUX SMI”) | Methods, systems and devices for reducing migration |
US10321841B2 (en) * | 2010-05-26 | 2019-06-18 | Flint Hills Scientific, Llc | Quantitative multivariate analysis of seizures |
US20110295332A1 (en) * | 2010-05-26 | 2011-12-01 | Flint Hills Scientific, L.L.C. | Quantitative multivariate analysis of seizures |
US9220887B2 (en) | 2011-06-09 | 2015-12-29 | Astora Women's Health LLC | Electrode lead including a deployable tissue anchor |
US9731112B2 (en) | 2011-09-08 | 2017-08-15 | Paul J. Gindele | Implantable electrode assembly |
GB2504196B (en) * | 2012-06-01 | 2015-04-29 | Bioinduction Ltd | Precision delivery of electrical therapy |
US9597520B2 (en) | 2012-06-01 | 2017-03-21 | Bioinduction Limited | Electrical stimulation of the carotid artery |
GB2504196A (en) * | 2012-06-01 | 2014-01-22 | Bioinduction Ltd | Precision delivery of electrical therapy |
US9370660B2 (en) | 2013-03-29 | 2016-06-21 | Rainbow Medical Ltd. | Independently-controlled bidirectional nerve stimulation |
US9782584B2 (en) | 2014-06-13 | 2017-10-10 | Nervana, LLC | Transcutaneous electrostimulator and methods for electric stimulation |
US10130809B2 (en) | 2014-06-13 | 2018-11-20 | Nervana, LLC | Transcutaneous electrostimulator and methods for electric stimulation |
US11612747B2 (en) | 2015-11-09 | 2023-03-28 | Bluewind Medical Ltd. | Optimization of application of current |
US11116975B2 (en) | 2015-11-09 | 2021-09-14 | Bluewind Medical Ltd. | Optimization of application of current |
US10105540B2 (en) | 2015-11-09 | 2018-10-23 | Bluewind Medical Ltd. | Optimization of application of current |
US11723579B2 (en) | 2017-09-19 | 2023-08-15 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement |
US10857356B2 (en) * | 2017-11-06 | 2020-12-08 | University Of Cincinnati | Transcutaneous spinal cord stimulation for treatment of psychiatric disorders |
US20190134386A1 (en) * | 2017-11-06 | 2019-05-09 | University Of Cincinnati | Transcutaneous spinal cord stimulation for treatment of psychiatric disorders |
US11717686B2 (en) | 2017-12-04 | 2023-08-08 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement to facilitate learning and performance |
US11478603B2 (en) | 2017-12-31 | 2022-10-25 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement to enhance emotional response |
US11273283B2 (en) | 2017-12-31 | 2022-03-15 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement to enhance emotional response |
US11318277B2 (en) | 2017-12-31 | 2022-05-03 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement to enhance emotional response |
EP4257180A3 (en) * | 2018-01-18 | 2023-12-20 | Pulsar Medtech Ltd. | External electronic patch for accelerating bone healing or regeneration after trauma |
US11364361B2 (en) | 2018-04-20 | 2022-06-21 | Neuroenhancement Lab, LLC | System and method for inducing sleep by transplanting mental states |
US11452839B2 (en) | 2018-09-14 | 2022-09-27 | Neuroenhancement Lab, LLC | System and method of improving sleep |
Also Published As
Publication number | Publication date |
---|---|
US6356788B2 (en) | 2002-03-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6356788B2 (en) | Apparatus and method for adjunct (add-on) therapy for depression, migraine, neuropsychiatric disorders, partial complex epilepsy, generalized epilepsy and involuntary movement disorders utilizing an external stimulator | |
US6205359B1 (en) | Apparatus and method for adjunct (add-on) therapy of partial complex epilepsy, generalized epilepsy and involuntary movement disorders utilizing an external stimulator | |
US6208902B1 (en) | Apparatus and method for adjunct (add-on) therapy for pain syndromes utilizing an implantable lead and an external stimulator | |
US6615085B1 (en) | Apparatus for adjunct (add-on) therapy of Dementia and Alzheimer's disease utilizing an implantable lead and an external stimulator | |
US6366814B1 (en) | External stimulator for adjunct (add-on) treatment for neurological, neuropsychiatric, and urological disorders | |
US10173065B2 (en) | Systems and methods for producing asynchronous neural responses to treat pain and/or other patient conditions | |
US7155279B2 (en) | Treatment of movement disorders with drug therapy | |
US7442183B2 (en) | Techniques for selective activation of neurons in the brain, spinal cord parenchyma or peripheral nerve | |
US6564102B1 (en) | Apparatus and method for adjunct (add-on) treatment of coma and traumatic brain injury with neuromodulation using an external stimulator | |
US9216290B2 (en) | Cranial nerve stimulation for treatment of substance addiction | |
US7003352B1 (en) | Treatment of epilepsy by brain stimulation | |
US6862479B1 (en) | Spinal cord stimulation as a therapy for sexual dysfunction | |
US6615081B1 (en) | Apparatus and method for adjunct (add-on) treatment of diabetes by neuromodulation with an external stimulator | |
AU2006276858B2 (en) | Selective nerve stimulation for the treatment of eating disorders | |
US20050049649A1 (en) | Electrical stimulation of the brain | |
US20060025841A1 (en) | Thalamic stimulation device | |
US20060241717A1 (en) | Treatment of movement disorders by extra dural motor cortex stimulation | |
WO2004037342A2 (en) | Electrical stimulation of the brain | |
US8401654B1 (en) | Methods and systems for treating one or more effects of deafferentation | |
US20230096373A1 (en) | Electrical optical medical lead | |
CN110870946B (en) | Device for stimulating the nucleus pulposus and/or the posterior bundle of the brain |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FPAY | Fee payment |
Year of fee payment: 4 |
|
REMI | Maintenance fee reminder mailed | ||
LAPS | Lapse for failure to pay maintenance fees | ||
STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20100312 |